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TAKING CLINICAL JUDGMENT OUT OF THE EQUATION: A CALL FOR THE 
STANDARDIZATION OF MCI DIAGNOSTIC CRITERIA AND CONSTRUCTION 
OF A MODEL TO PREDICT CONVERSION TO DEMENTIA 
Adam Gerstenecker 
June 26, 2014 
Although the diagnostic criteria for mild cognitive impairment have evolved 
considerably since their inception, they remain varied and able to be interpreted and 
implemented in different ways depending on the judgment of the clinician.  Because of 
this issue, a wide range of incidence, prevalence, and conversion rates are found in the 
research literature. Using data collected from 400 patients with amnestic mild cognitive 
impairment, limitations inherent in current mild cognitive impairment diagnostic criteria 
were addressed. First, using Alzheimer’s Disease Neuroimaging Initiative diagnostic 
criteria, an equation was constructed to predict conversion from mild cognitive 
impairment to dementia by analyzing the predictive ability of variables representative of 
a number of categories (i.e., demographic, psychiatric, functional, biomarker, imaging, 
and cognitive). This model accounted for over 60% of variance in conversion and 
exhibited an area under the curve of 0.93. Then, separate models were constructed using 
different applications of the current diagnostic criteria for mild cognitive impairment. As 
expected, criteria utilizing a one standard deviation clinical cutoff on a measure of 
delayed verbal recall in combination with the allowance for some functional change (i.e.,
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 scores ≤5 on the Functional Activities Questionnaire) exhibited the greatest utility of any 
combination of diagnostic criteria. Taken together, these results indicate that statistical 
equations can be constructed to predict conversion from mild cognitive impairment to 
dementia and be tailored for widespread clinical use. Moreover, these results show that 
















RESEARCH QUESTIONS AND HYPOTHESES……………………………………..26 
 
























LIST OF TABLES 
 
 
TABLE           PAGE 
 
1. MCI Diagnostic Criteria and Current Recommendations…………………………….  
2. MCI-R Subtype and Etiology  
3. Recommendations from the Alzheimer’s Group.......................................................44 
4. Biomarkers Under Examination for AD.........................................69 
5. MCI Criteria Incorporating Biomarkers.......................................87 
6. Current Recommendations for Standardization of MCI Diagnostic Criteria 
7. Diagnostic Criteria for Classification Systems.  
8. Demographics for MCI Patients by Classification System. 
9. Neurocognitive Model using ADNI Backward Elimination Method 
10. Imaging Model using ADNI Backward Elimination Method 
11. Final Model using ADNI Criteria, Hand Selected Method 
12. Number and Percentage of Patients Identified as Normal, MCI, and Mild AD and                                           
\     Converting from MCI to dementia.  
13. Final Model using ADNI Criteria, Backward Elimination Method 
14. Final Model using Proposed Criteria #1(Model #1). 
15. Final Model using Proposed Criteria #2 (Model #2). 
16. Final Model using Proposed Criteria #3 (Model #3). 
17. Performance of Models across Classification System (β, p). 
18. Performance of Models across Classification Systems (Pseudo R2, AUC). 







Mary and the Diagnostic Process 
 Mary is a 67-year-old Caucasian woman whose family is concerned that she is 
“having trouble with her memory.”  Her daughter reports that Mary exhibits some 
difficulty “keeping up” in conversations and recently “lost track of her hand” while 
playing bridge.  This was noted as especially distressing to Mary’s daughter because 
Mary has been an avid bridge player for over 40 years and “quite the card shark.”  In 
contrast to his sister, Mary’s son reports that his mother’s memory is “no different from 
other people [her] age.”  When Mary is asked about her memory, she reports “it is just 
fine.”  Mary’s primary concern is “feeling depressed” and “not being able to stay asleep 
at night because [she] worries too much.”   
After completing a neuropsychological battery, Mary exhibited average 
performance when compared to age- and education-matched peers on a test of general 
cognitive functioning (25th percentile).  No subscale scores fell more than 1.5 standard 
deviations (SD) below the mean.  However, on a more comprehensive test of memory, 
Mary exhibited below average immediate (20th percentile) and delayed recall (15th 
percentile).  Mary’s family reports that she is completely independent in both higher- and 
lower-order activities of daily living (ADL), but Mary was not administered a functional 
measure as part of her neuropsychological evaluation.  Given these observations, her 
attending physician recommended she be diagnosed with mild cognitive impairment   
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(MCI) and prescribed Aricept (a medication designed to target memory function in older 
adults).  However, the neuropsychologist who administered the tests recommended she 
be re-evaluated in 6-9 months after being treated for depression and anxiety.  
Nevertheless, Mary was diagnosed with MCI, the diagnosis recorded in her medical 
records, and her family educated about the diagnosis and increased risk MCI patients 
have for progression to a dementia syndrome.   
Study Purpose 
The purpose of the current study is to demonstrate how MCI diagnostic criteria 
are affected by a lack of standardization and clinical judgment.  This issue will be 
discussed in detail, and a potential solution proposed.  This solution will take the form of 
two statistical models: (1) a “screening” model designed to increase the standardization 
of diagnostic criteria, and (2) a “conversion” model designed to fully remove clinical 
judgment from the diagnostic process.  The screening model will primarily be based upon 
the most widely used and accepted MCI clinical diagnostic criteria.  However, particular 
emphasis will be given to decreasing the ambiguity of these criteria so they can be 
applied in a consistent manner.  For the conversion model, data from a full clinical and 
medical evaluation will be used to construct a mathematical equation designed to identify 
people at particular risk of converting from MCI to dementia.  The proposed conversion 
model will be based upon the combined predictive power of numerous factors including 
neuropsychological performance, neuroimaging, biomarkers, behavioral abnormalities, 





Mary’s Diagnosis and Clinical Judgment 
 Mary’s case illustrates the prominent role clinical judgment assumes in the 
evaluation of older adults with suspected cognitive impairment.  But, how can clinical 
judgment play such a prominent role in a process so seemingly driven by data?  The 
answer is simple: statistical models of diagnostic prediction are not readily available to 
professionals nor used by professionals when working with older adults.  Consequently, 
these professionals often rely on heuristics.  In short, heuristics are mental tools based on 
prior experience and knowledge that are used to reduce cognitive burden in decision 
making and to allow for faster and often correct decisions (Shah & Oppenheimer, 2008).  
However, by introducing personal heuristics into the decision-making process, personal 
cognitive biases are also introduced and contribute to errors in judgment (Tversky & 
Kahneman). Consequently, two clincians with the best interests of a patient in mind could 
have quite different diagnostic impressions of the very same set of presenting symptoms.  
For example, Mary’s physician frequently encounters patients whose families 
report memory loss.  More often than not, these patients have dementia or MCI.  This 
leads the physician to develop a heuristic about patients similar to Mary.  Thus, when 
Mary exhibited some minor impairment in memory, the heuristic developed by her 
physician contributed to Mary being diagnosed with amnestic MCI.  In contrast to the 
physician, the neuropsychologist working with Mary frequently encounters patients 
reporting clinically significant symptoms of depression and anxiety.  More often than not, 
these patients experience problems with memory and/or attention.  Consequently, the 
neuropsychologist developed a heuristic that borderline or mildly impaired memory may 
be a byproduct of depression and not necessarily caused by a neurodegenerative disorder.  
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As can be seen, both the physician and neuropsychologist utilized prior experience in 
forming divergent viewpoints of Mary’s condition.   
Clinical versus Statistical Judgment  
 The Legacy of Paul Meehl 
The question of clinical versus statistical judgment was first brought to 
prominence in 1954 after Paul Meehl published a book comparing the two methods.  
Meehl classified clinical judgment as judgments based on the prior experience of a 
human judge.  On the other hand, human decision-making is eliminated in the statistical 
method in favor of empirical relations between obtained data and the criterion.  But, 
basing decisions on a statistical model entails more than simply applying automated 
decision rules just as programming computers entails more than mimicking clinical 
judgment.  The key point is that in order for a decision method to be considered 
statistical, it must not only be automated but must also be based on empirically 
established relationships (Dawes, Faust, & Meehl, 1989).    
 Since Meehl’s (1954) seminal publication, the number of investigations 
examining clinical versus statistical judgment has grown to more than 150, and the results 
remain consistently in favor of the statistical method.  In the few studies in which a 
preference for clinical judgment was noted, alterations to the statistics used in the 
prediction equation had a tendency to tip the scales in favor of the statistical method 
(Dawes, 2005).  In sum, the role of clinical versus statistical judgment has been well 
studied in psychology, and the evidence points to the clear superiority of the statistical 




Clinical Versus Statistical Judgment in the Diagnosis of MCI 
  Returning to the diagnosis of Mary, it is apparent clinical judgment has led to two 
contradictory hypotheses made by her attending physician and neuropsychologist: (1) that 
she should be diagnosed with MCI because of her memory decrements and (2) that she 
should not be diagnosed with MCI because her suboptimal memory may be a byproduct 
of depression and anxiety.  How such contradictory views can be formed has already 
been discussed, but a solution not formally proposed.  As will be outlined in the next 
section of this paper, the lack of standardization of the existing diagnostic criteria needs 
to be addressed before the development of a statistical model designed to predict 
conversion from MCI to dementia.   
Because of the ambiguity of diagnostic criteria, clinical judgment is heavily relied 
upon when determinations about an MCI diagnosis are made.  This leads to a number of 
potential problems that affect both clinical practice and research studies: (1) people with 
MCI will not receive treatment until more serious cognitive decline is exhibited, (2) 
people will be misdiagnosed as having MCI and be given unnecessary treatment, (3) 
samples included in research studies will be representative of different populations 
leading to the decreased generalizability of the findings and how they relate to MCI, (4) 
the prognosis of MCI patients remains unclear, and (5) reliable estimates of MCI 
prevalence cannot be obtained.  A statistical model can help in this regard.  However, 
before a discussion of MCI diagnostic criteria and the application of a statistical model 





Predementia: From “Normal” Cognition to Dementia 
As the brain ages, many older adults experience changes in cognition.  It is only 
when changes exceed what is expected that normal cognition is thought to be 
compromised.  As many as 1 in 7 adults over the age of 71 are currently living with 
dementia (Plassman et al., 2007), and this number may triple by the year 2050 with older 
adults over the age of 85 being most affected (Hebert, Scherr, Bienias, Bennett, & Evans., 
2003).   Although numerous different dementia syndromes have been identified, 
Alzheimer’s disease (AD) is the most well-known and widely researched type of 
dementia.  But transition from normal cognition to AD is not a one-step process, and 
“preclinical stages” (changes in the brain that occur prior to the onset of clinically 
detectable symptoms) are thought to precede the disease and may last upwards of 20 
years.  Once these preclinical changes become associated with observable cognitive or 
functional deficits, a predementia syndrome is said to be present.  To date, a number of 
predementia syndromes have been proposed, but relatively few have thoroughly 
delineated research criteria that yield the opportunity for ongoing study and the 
examination of rates of progression to dementia (Panza et al., 2005).   
Mild Cognitive Impairment: The Evolution of a Diagnosis Reflects Limitations 
Of all the terms used to describe predementia syndromes, the most well-known 
and extensively researched is MCI.  Simply stated, MCI is a term used to describe 
cognitive decline that does not significantly interfere with daily functioning and, 
therefore, does not meet criteria for dementia.  Given this broad definition, the potential 
exists for MCI to be a term that unifies all other terms used to classify predementia 
syndromes and declines in cognition not associated with normal aging.  However, this 
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was not always the case as memory impairment was originally a necessary diagnostic 
component.  By having this stipulation, MCI was more reflective of a pre-AD stage than 
a preclinical syndrome related to general cognitive impairment.  Currently, MCI is no 
longer conceptualized as a unitary construct dependent on memory impairment but a 
syndrome with multiple subtypes: amnestic-MCI (aMCI); multiple domains, slightly-
impaired-MCI (mdMCI); and single, non-memory-domain-MCI (snMCI).   
 MCI Conceptualized: Contributions of the New York University Group 
MCI was originally conceptualized by a research group from New York 
University in 1991 (Flicker, Ferris, & Reisberg, 1991) using stages from the Global 
Deterioration Scale (Reisberg et al., 1982) (Panza et al., 2005).  Six stages comprise the 
Global Deterioration Scale: Stage 1 (no cognitive decline), Stage 2 (very mild cognitive 
decline), Stage 3 (mild cognitive decline), Stage 4 (moderate cognitive decline), Stage 5 
(moderately severe cognitive decline), and Stage 6 (severe cognitive decline).  Although 
the Global Deterioration Scale was designed to assess degenerative dementia and 
describe its stages, it was noted by the group from New York University that a number of 
patients fell into stages 2 and 3 and that these patients were exhibiting mild cognitive 
impairment instead of dementia.   
 Diagnostic Criteria and Impairment Cutoffs: Contributions of the Max Planck I
 nstitute  
As previously noted, diagnostic criteria were not proposed when the term MCI 
was conceptualized because the label of MCI was only applied to patients scoring in a 
designated range on a single measure (i.e., the Global Deterioration Scale). In 1992, 
Zaudig attempted to reclassify MCI according to existing diagnostic systems.  After 
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administering the Structured Interview for the Diagnosis of Dementia of the Alzheimer 
Type, multi-infarct dementia, and dementias of other etiology (SIDAM: Zaudig et al., 
1991; Zaudig & Hiller, 1991) to a sample of 150 randomly selected older adults living in 
Germany, patients with cognition anddaily functioning consistent with dementia and MCI 
were identified.   
Using the Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition 
Revised (American Psychiatric Association, Diagnostic and Statistical Manual of Mental 
Disorders, 3rd ed., revised [DSM-III R], 1987) criteria, two types of MCI patients were 
classified.  Type 1 patients (MCI Type 1) exhibited characteristics identical to the DSM-
III-R diagnostic criteria for Amnestic Syndrome: memory impairment (short- and long-
term memory) but no impairments in any other cognitive domain.  The other type (MCI 
Type 2) exhibited impairments to memory and another cognitive domain.   
Using International Statistical Classification of Disorders (World Health 
Organization, International Statistical Classification of Disorders and Health Related 
Problems, 10th Revision [ICD-10], 1992) criteria, three “types” of MCI patients were 
classified.  Type 1 and Type 2 patients were identical to those outlined by DSM-III-R 
criteria.  Type 3 patients (MCI Type 3), however, could display characteristics of either 
MCI Type 1 or MCI Type 2 along with accompanying deterioration in emotional control, 
social behavior, or motivation.  Using these definitions in combination with performance 
on the SIDAM, optimal scores for characterizing patients as normal, MCI Type 1, MCI 
Type 2, MCI Type 3, and demented were reported.  As can be seen, this work represented 
a critical step forward in advancing a statistical approach to diagnosing MCI.  However, 
as will be detailed below, subsequent work did not capitalize on this.    
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 MCI Diagnostic/Research Criteria: The Contributions of Ronald Petersen    
In what has become known as the “Petersen criteria” or “Mayo criteria” (Petersen 
et al., 1997; Petersen et al., 1999) the first diagnostic/research criteria for MCI were 
developed: (1) memory complaint, (2) normal daily functioning, (3) normal general 
cognitive function, (4) abnormal memory for age, and (5) not demented (see Table 1).  
Although this represented an important advance in the development of the MCI construct, 
a number of limitations were present.  First, memory impairment was deemed necessary, 
but many older adults with impaired cognition do not have a primary impairment in 
memory.  Instead, many have primary impairment in other areas of cognition (e.g., 
executive dysfunction).  Furthermore, evidence exists that in some patients, changes to 
executive function precedes the onset of changes in memory (Carlson et al., 2009).  
Second, clinical judgment is required on the part of the patient due to a subjective 
memory complaint being a necessary criterion.  This means memory impairment need not 
only be present but also judged as present and reported by the patient.  Third, “normal” 
daily functioning must be exhibited, but what constitutes “normal” remains a judgment of 
the clinician.  Moreover, some declines in daily functioning are common in non-
demented older adults, and this further complicates the reliance on clinical judgment.  
Finally, phrases such as “normal general cognitive function” and “abnormal memory for 
age” do not specify what constitutes normal from abnormal and, once again, lead to an 
overreliance on clinical judgment.  Is 1.0 standard deviation (SD) below the mean 
abnormal? Is 1.5 SD below the mean abnormal? Should age and education be taken into 
account?  Answers to these questions are not clear from the criteria and, therefore, 
clinicians must use their best judgment to decide.   
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 First Key Symposium 
At the First Key Symposium in Stockholm, Sweden, in 2003, it was 
acknowledged that MCI could have multiple etiologies and subtypes that are not mutually 
exclusive and not necessarily related to a degenerative neurological disorder such as AD 
(Winblad et al., 2004) (see Table 2).  Another recommendation from this consensus 
conference had to do with the second Petersen criteria (normal daily functioning).  As a 
result, patients with early and subtle changes to daily functioning could still be 
considered for an MCI diagnosis.  Moreover, a concrete definition of “subtle” was not 
explicitly stated and a description about how to go about assessing these subtle changes 
to daily functioning was not given.  Consequently, the best way to assess for declines to 
daily functioning and the threshold for “subtle changes” remained highly influenced by 
clinical judgment.  
 Latest Recommendations for Research/Diagnostic Criteria  
The most current recommendations for diagnostic/research criteria for MCI come 
from a workshop organized by the National Institute on Aging and Alzheimer’s 
Association (NIA/AA) (Albert et al., 2011).  These criteria are very similar to original 
Petersen criteria, and many of the issues regarding standardization and overreliance on 
clinical judgment found in the original Petersen criteria remain unchanged (see Table 3).   
Impairment in MCI: Overreliance on Clinical Judgment  
In the most recent recommendations given for MCI diagnostic criteria (Albert et 
al., 2011), impairment can be present in one or more cognitive domains (Table 3).  The 
following description of impairment was given by the NIA/AA workgroup: “There 
should be evidence of lower performance that is greater than would be expected for the 
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patient’s age and educational background.  If repeated assessments are available, then a 
decline in performance should be evident over time” (Albert et al., 2011, p.  271). A 
critique of this definition has to do with how much clinical judgment is needed to 
interpret the description.  Specifically, what constitutes “lower performance?” Since it is 
not explicitly stated, this question is left to the judgment of the clinician.  Moreover, 
reference is given to a “decline in performance over time” but no specifications as to 
what constitutes decline.  Does this mean one, five, or ten percentage points in relation to 
age- and education-matched peers? Once again, this determination is left to the judgment 
of the clinician.    
 Later in the Albert et al (2011) paper, it is noted: “Cognitive testing is optimal for 
objectively assessing the degree of cognitive impairment for an individual.  Scores on 
cognitive tests for individuals with MCI are typically 1 to 1.5 SD below the mean for 
their age- and education-matched peers on culturally appropriate normative data (i.e., for 
the impaired domain(s), when available).  It is emphasized that these ranges are 
guidelines and not cutoff scores” (Albert et al., 2011, p.  273). It is interesting that this 
recommendation is not included with the actual diagnostic criteria and that the 
impairment ranges are considered “guidelines and not cutoff scores.” By setting clear 
impairment cutoffs, the diagnosis of MCI can be more standardized and, therefore, less 
reliant on clinical judgment.  Moreover, the difference between a standard deviation of 1 
SD and 1.5 SD below the mean is a relatively wide range.  In terms of percentiles, this 
places the range between the 7th and 16th percentile, meaning the patient would have to 
score worse than either 84% or 93% of the population after correcting for age and 
education.  Consequently, even for clinicians choosing to use less clinical judgment by 
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following the guidelines, judgments must be employed in order to choose which cutoffs 
to use.   
 Another problem with this description of impairment is the failure to take into 
account premorbid intelligence.  Simply stated, premorbid intelligence is an estimate of a 
person’s cognitive functioning before changes in cognition started to appear.  This need 
to evaluate current cognition in relation to pre-morbid intelligence is highlighted by the 
Guidelines for the Evaluation of Dementia and Age-Related Cognitive Decline 
(American Psychological Association, 2011).  Although these guidelines are described as 
aspirational and not enforceable, guideline 4  states that psychologists should attempt to 
estimate premorbid intelligence when measuring cognitive changes in individuals.  
Without an estimate of premorbid intelligence, determining a change in cognition is 
difficult and left to the judgment of the clinician.  For instance, an older adult with an 
estimated pre-morbid Intelligence Quotient (IQ) falling into the 16th percentile would be 
demonstrating no decline in relation to peers using a 1.0 SD cutoff.  However, the same 
older adult would be considered impaired using the recommendations from Albert et al.  
(2011).  In contrast, interpretation would be quite different for an older adult with an 
estimated premorbid IQ falling at the 84th percentile.  For this patient, performance on 
cognitive measures falling at the 50th percentile represents a fairly substantial decline in 
cognition, and performance falling into the 16th percentile represents a change in 
cognition of two SD.  Without taking into account pre-morbid intelligence, the same 
impairment threshold would be used when, in reality, the first patient is exhibiting no 
changes in cognition while the second patient is exhibiting drastic changes in cognition.     
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 Ideally, obtaining an estimate of premorbid IQ would be as easy as reading a 
WAIS report that was administered to the patient sometime in the past, but these kinds of 
records are rarely available.  Instead, a neuropsychologist should evaluate a skill that is 
relatively resistant to the changes in cognition associated with MCI and dementia.  This is 
most easily accomplished by evaluating reading ability because reading ability does not 
significantly differ in relation to peers even in older adults diagnosed with mild dementia 
(McGurn et al., 2004).  However, minor changes in reading have been noted early in the 
course of dementia, and these changes increase as the disease progresses (Cockburn et al., 
2000; O’Carroll et al., 1995; Patterson, Graham, & Hodges, 1994).  Consequently, for 
patients with moderate to severe dementia, reading ability cannot be relied upon to yield 
an accurate estimate of pre-morbid intelligence.   
 Measures such as the American National Adult Reading Test ANART (Nelson & 
O’Connell, 1978) provide a good example of how to best assess reading to gain an 
estimate of pre-morbid intelligence.  The ANART contains 50 low-frequency/irregular 
English words (e.g., ache and thyme), and the patient is instructed to read aloud each 
word with the number of words correctly pronounced comprising a total score.  
Normative data correcting for age, gender, and education are available (Kiely et al., 
2011).  Other techniques such as using a statistical model designed to estimate premorbid 
intelligence from demographic variables are available (Crawford, Millar, & Milne, 2001).  
Although reading tests such as the ANART have been shown to yield the most accurate 
estimates of premorbid IQ, measures combining reading ability, best performance, and 
demographic variables are needed and have the potential to be more accurate than a test 
of reading ability used in isolation (Griffin et al., 2002).   
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 Turning again to the example case, it can clearly be demonstrated how clinical 
judgment must be used given the ambiguous nature of the current MCI diagnostic 
criteria.  Even following the recommendations given by the Alzheimer’s workgroup (1 
SD to 1.5 SD below the mean), clinical judgment is still needed in determining a 
diagnosis.  Mary exhibited general cognitive functioning falling at the 25th percentile and 
immediate memory falling at the 20th percentile.  No clinical judgment is needed because 
these scores are above both recommended cutoffs. However, she exhibited delayed 
memory falling at the 15th percentile, and this score falls into the gray area between 1 SD 
and 1.5 SD below the mean.  Does this mean that impairment is present and a diagnosis 
of amnestic MCI applicable? Unfortunately, clinical judgment will be needed to decide.  
It is also difficult to ascertain the significance of Mary’s scores because an estimate of 
premorbid intelligence was not obtained.  Is Mary’s premorbid intelligence average, 
below average, or above average? This information would certainly give a better 
perspective about her current scores, but this information is not available.   
NIA/AA Recommendations and Biomarkers and Imaging 
Criteria from the Alzheimer’s Workshop are divided into two parts: one 
containing reference to biomarkers and imaging and one not containing reference to 
biomarkers and imaging.  Biomarkers and imaging under examination and MCI criteria 
incorporating biomarkers and imaging are listed in Tables 4 and 5, respectively.  Taken 
together, these criteria offer an exciting advancement in the diagnosis of MCI.  However, 
the inclusion of biomarkers and imaging is still considered an exploratory step.  As noted 
by Albert and colleagues, this inclusion is to “determine the likelihood of cognitive and 
functional progression for an individual MCI patient to a more severe stage of MCI or to 
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dementia, and the likelihood that this progression will occur within a defined period” (pg.  
275). Albert and colleagues go on to note that imaging and biomarkers are not validated 
in MCI and that studies are largely confined to the examination of patients with AD.  For 
studies examining MCI patients, few have compared biomarkers and imaging with each 
other or with histopathologic confirmation.  Furthermore, studies combining multiple 
biomarkers and imaging data have not been conducted.  Taken together, this means that 
predictive studies regarding imaging and biomarkers in relation to MCI are greatly 
needed to advance diagnostic accuracy.  (A brief review of imaging and biomarkers in 
AD can be found later in this proposal).      
MCI: Estimates of Prevalence and Incidence are Inconsistent   
Earlier it was stated that one effect of clinical judgment could be that the samples 
used in MCI research may, in fact, be representative of quite different populations.  This 
critique is well supported by research on the prevalence and incidence of MCI in the 
general population.  From 1995-2009, nine studies on MCI incidence rates were 
conducted in North America, South America, and Europe.  Although each of these nine 
studies used similar diagnostic criteria, application of these criteria varied from study to 
study.  As noted in a review by Luck et al.  (2010), MCI diagnostic criteria were modified 
in four of the nine studies.  In three studies, a subjective report of cognitive impairment 
was not required, and in one study a subjective report of cognitive impairment and 
preserved daily functioning were not required (the daily functioning criteria used in this 
study is similar to the most recent diagnostic recommendations made by the Alzheimer’s 
workgroup.).  Impairment thresholds also varied among studies. Performance less than 
1.5 SD below the mean, less than 1.0 SD below the mean, and less than the 10th 
16 
 
percentile in relation to age-, education-, and sometimes gender- and race-corrected 
scores were all used (Luck et al., 2010).        
 Given the wide array of differing applications of the MCI diagnostic criteria in 
incidence studies (both for Petersen and MCI-R criteria), it is not surprising the range of 
estimates of MCI incidence is quite large.  For any MCI type, estimates range from 8.5-
76.8 per 1,000 person-year (Ravaglia et al., 2008; Solfrizzi et al, 2004; Tervo et al., 2004; 
Chaves et al., 2009; Caracciolo et al., 2008; Manly et al., 2008; Verghese et al., 2006; 
Busse et al., 2003; Larrieu et al., 2009; Lopez et al., 2003).  Estimates for amnestic MCI 
range from 8.5-40.6 per 1,000 person-year while estimates of non-amnestic MCI range 
from 28-36.3 per 1,000 person-year.  Higher estimates were noted in studies that did not 
require a subjective report of cognitive impairment.  As can be seen from these estimates, 
the incidence of MCI in the population is not well understood and reflects a need for the 
standardization of the diagnostic criteria.  Age, education, and vascular risk factors were 
consistently associated with increased incidence of MCI.  No studies on the incidence of 
MCI using criteria proposed by the Alzheimer’s workgroup have yet been conducted. 
 Several studies have been conducted comparing the prevalence of MCI in the 
population according to both MCI and MCI-R criteria.  As with the incidence studies 
discussed above, the interpretation of the criteria vary from study to study and also 
highlight the need for standardized criteria.  For instance, in a sample of 3,327 older 
adults over the age of 75 who were receiving care from a general practitioner, the 
prevalence of MCI was 15.4% using Petersen criteria and 25.2% using MCI-R criteria 
(Luck et al., 2007).  The SIDAM was used to evaluate cognitive impairment, and domain 
specific cognitive impairment was considered present if performance fell more than 1 SD 
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below the mean using age- and education-corrected scores.  The SIDAM-ADL scale was 
used to evaluate daily functionin, and patients with one or no impairments on the 14 
SIDAM-ADL items were considered functionally unimpaired.  Significant risk factors 
included age, vascular disease, depression, and APOE4 genotype.   
 In a study of 883 older adults over the age of 60 receiving care from a general 
practitioner, the prevalence of MCI was 16.6% using MCI-R criteria but fell to 3% when 
using Petersen criteria (Artero et al., 2006).  A computerized neuropsychological 
evaluation assessing a number of cognitive domains was used to evaluate for cognitive 
impairment.  Patients were considered impaired if performance fell more than 1.5 SD 
below age- and education-corrected scores on a memory or other cognitive task.  Daily 
functioning was required to be “essentially normal” (Artero et al., 2006, p.  467).  
However, specifics about the evaluation of daily functioning were limited to the 
following quote: “A validated activity of daily living scale with finely graded hierarchical 
subscales was used to assess alterations in everyday functioning in collaboration with 
both subjects and caregivers” (Artero et al., 2006, p.  466).   
 The two studies outlined above were chosen to highlight how lack of standardized 
criteria can lead to differing estimates using Petersen and MCI-R criteria in a similar 
sample (i.e., patients of general practitioners).  In the study by Luck et al (2007), the 
authors judged impairment to be present if scores fell more than 1 SD below the mean 
using age- and education-corrected scores on a neuropsychological test.  However, in the 
Artero and colleagues’ study, the authors did not judge impairment to be present until 
age- and education-corrected scores were more than 1.5 SD below the mean.  Evaluation 
of daily functioning was also not uniform between the two studies.  In Luck and 
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colleagues’ study, a patient’s daily functioning was judged as impaired if difficulties in 
two or more areas were displayed.  However, daily functioning was required to be 
essentially normal by Artero and colleagues.  Although comparisons between the 
prevalence estimates noted in these two studies are not appropriate due to the difference 
in ages of the samples (75+ vs.  60+), it can easily be seen how clinical judgment would 
lead to different prevalence estimates even when using an identical sample.  No studies 
on the prevalence of MCI using criteria proposed by the Alzheimer’s workgroup have yet 
been conducted. 
Conversion from MCI to Dementia: Varying Estimates  
 As with estimates of incidence and prevalence, the role of clinical judgment in the 
interpretation of MCI diagnostic criteria has contributed to uncertainty regarding 
prognosis.  For some patients diagnosed using current criteria, an improvement in 
cognition can be expected.  For others, cognition will remain stable.  For still others, 
cognition will continue to decline until a diagnosis of dementia is warranted.  However, 
these estimates vary widely in the research literature.  A review of studies of dementia 
conversion well illustrates this point.   
 In a study using original Petersen criteria, 32.2% of patients diagnosed with MCI 
progressed to dementia within two years (Amieva et al., 2004).  In this study, general 
cognitive functioning was judged to be intact for patients with at least a primary school 
education and scoring >25 on the MMSE.  For patients with less education, general 
cognitive functioning was judged as intact if scores were >23 on the MMSE.  For both 
education groups, domain specific impairment was judged as present if scores were more 
than 1.5 SD below the mean using age- and education-corrected scores on either a test of 
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working memory or semantic fluency.  No dependency for basic ADLs and slight 
dependency for higher-order ADLs were required for an MCI diagnosis.  In another study 
in which a differing interpretation of original Petersen criteria was used (i.e., MMSE 
scores <25 regardless of education for intact general cognitive functioning, 1.0 SD cutoff 
for domain specific impairment, and normal daily functioning), a conversion rate of 27% 
was noted over the course of ten years, and only 15% of patients progressed to dementia 
over the first two years (Ganguli et al., 2004).   
 MCI-R criteria have been noted as exhibiting better predictive validity of 
conversion to dementia (sensitivity of 95% and specificity of 66%) than the original 
Peterson criteria (sensitivity of 5% and specificity of 91%) when the same impairment 
cutoffs are used for both  groups (Artero et al., 2006).  However, issues are also present 
with MCI-R criteria as the application of these criteria can lead to strikingly different 
conversion estimates.  For instance, when using cutoffs of more than 1 SD and more than 
1.5 SD below the mean on the SIDAM for both Petersen and MCI-R criteria, the best 
predictive validity (sensitivity of 74% and specificity of 73%) was observed when MCI-R 
criteria was coupled with a 1 SD cutoff (Busse et al., 2006).  When using a 1.5 SD cutoff, 
specificity increased to 86.1% but at the expense of a decrease in sensitivity to 40.4%.  
Overall, conversion rates varied by 45% depending on which diagnostic criteria were 
used and how they were applied.  No studies of rates of conversion from MCI to 






Proposing an Statistical Model: A Two-Step Process 
 The Two Steps 
 As outlined in Tables 2 and 3, the etiology of MCI (i.e., degenerative, vascular, 
metabolic, traumatic, psychiatric, and other) can vary from patient to patient.  These 
etiologies also have significant long-term implications.  For example, if the cause of MCI 
is a degenerative brain disorder (i.e., AD or other types of dementia), then MCI is 
considered a predementia syndrome and will continue to progress until the death of the 
patient; however, if the cause is reversible (i.e., metabolic and psychiatric), treatments 
can be applied to help the patient’s cognition remain stable or improve.  As a concept, 
MCI is designed to identify patients in the first category: those who will eventually go on 
to develop a dementia syndrome.  But in practice, patients in both groups are diagnosed 
with MCI.  This means patients with cognitive decline stemming from depression, 
anemia, thyroid disease, and/or a vitamin deficiency will be diagnosed the same as 
patients in the preclinical stages of a dementia syndrome.   
 Using a statistical model, MCI patients could be classified based upon risk for 
conversion.  Essentially, this would divide MCI into two groups based upon risk 
determined by comparison to a single cut-score. For one group, risk for conversion would 
be high. For the other group, risk for conversion would be low.  Furthermore, through the 
application of screening and conversion models (explained below), issues present in 
current research studies could be mitigated to a large degree.  To construct such a model, 
two steps are needed.  Step 1 would involve constructing a “screening” model, and Step 2 




 Step I: Screening Patients for Application of a Conversion Model 
 A screening model used to identify patients to be evaluated by a conversion 
model should be weighted in favor of including false-positives over false-negatives.  This 
is because a screening model is aimed at determining which individuals need a more 
thorough and expensive evaluation so the conversion model can be applied.   However, 
for the purpose of ease and consistency among samples used in research studies, the 
importance of using standardized criteria with the least amount of reliance on clinical 
judgment cannot be overstated (see Table 6 for recommendations).   
 First, it is recommended that patient judgment (subjective complaints), family 
judgment (family reports of decline), informant judgment (reports from non-family 
members that decline is present), and clinical judgment (reports from providers) be 
excluded from a screening model.  Second, objective evidence of impairment should be 
standardized and pre-morbid IQ taken into account.  As recommended by Busse et al. 
(2006), a cutoff of 1.0 SD below the mean should be used to best optimize the number of 
older adults identified as at risk for conversion to a dementia syndrome.  Although this 
cutoff inflates the number of false-positives to a degree, it reduces the risk of not 
identifying patients who will later go on to develop dementia.  Given the opportunity to 
treat and study these predementia patients, the increased rate of false-positives seems an 
acceptable compromise.  Moreover, application of the second model (i.e., conversion 
model) would further mitigate the increased rate of false-positive results.  In other words, 
those who were falsely identified as MCI by the simple screening model could later be 
correctly identified using the more complex conversion model.  Third, an older adult 
should not be considered impaired if scores do not fall more than 1.0 SD below estimates 
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of pre-morbid IQ.  As outlined earlier in this proposal, older adults who exhibited 
cognitive abilities at the 10th percentile when they were 20 years old should not be 
considered impaired if performance falls at the 10th percentile when they are 70 years old.  
Fourth, functional abilities and daily functioning should be evaluated with a functional 
measure validated on the patient population being assessed.  Moreover, essentially 
normal daily functioning should not be required because older adults can experience 
some changes in functional abilities not related to cognitive impairment and, therefore, 
not indicative of dementia (similar to MCI-R criteria).  With these recommendations, 
clinical judgment can be taken out of a screening model.  Furthermore, the simplicity of 
the proposed screening model would work to lessen the constraints of human cognitive 
limitations.   
 The screening model based on the above recommendations would have four 
components: (1) scores >1 SD below mean age- and education-corrected scores on a test 
of general cognitive functioning (i.e., ADAS-COG);  (2) scores ≤1 SD below mean age- 
and education-corrected scores on a measure evaluating a specific cognitive domain (i.e., 
memory); (3) performance on domain specific test is ≤1.5 SD below estimate of 
premorbid intelligence; and (4) no difficulty or mild difficulty in any daily functioning 
domain as determined by scores on an empirically validated functional measure.   
 By using Mary’s scores corrected for age and education as an example, it can be 
demonstrated how this screening model could be used for amnestic MCI.  On a test of 
general cognitive functioning, Mary scored in the 25th percentile.  This score indicates 
that her general cognitive functioning is not considered impaired so a + is noted for the 
first part of the model.  On tests of memory, she scored in the 20th percentile for Total 
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Recall and in the 15th percentile for Delayed Recall.  Her score on Delayed Recall is ≥1 
SD below the mean so a + is also noted for the second part of the model (domain specific 
impairment).  Although not administered an empirically validated functional measure, 
Mary’s daily functioning was reported as normal so a + is noted for the fourth part of the 
model.  However, by relying on family reports, family judgment has been used to 
determine if a + was warranted for the parts of the equation related to ADL and IADL 
functioning.  This emphasizes the importance of using an empirically validated functional 
measure as part of a neuropsychological assessment so clinical judgment can be taken out 
of the equation.   
 So far, Mary has received a + on all addressed parts of the model.  However, 
Mary’s premorbid intelligence was not assessed.  Because of this oversight, the screening 
model cannot be completed.  If, for example, Mary’s performance on the ADAS-COG 
(25th percentile) is reflective of her premorbid intelligence, she would receive a – for the 
third part of the equation because her Logical Memory score is within 1 SD.  In contrast, 
a + would be warranted if her performance on the ADAS-COG is not reflective of her 
premorbid intelligence.  For example, if Mary’s premorbid intelligence fell at the 67th 
percentile, her score on Delayed Recall would be more than 1 SD lower.  Consequently, a 
+ would be noted for the third part of the model.  However, the screening model is only a 
step to identify people most in need for evaluation from the second (conversion) model.  
If any question arises about a patient, the steps needed to apply the second model should 
be taken.  For example, the screening model was not able to be fully completed for Mary 
because her premorbid intelligence was not evaluated.  However, a discrepancy was 
noted between scores on tests of general cognitive functioning and memory.  
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Consequently, it is recommended that Mary take the steps needed for the conversion 
model to be applied.    
 Step II: Constructing a Model to Predict Conversion to Dementia 
 Statistical models for predicting dementia risk in the older adult population can be 
found in the literature.  The models with the best predictive validity are multifactorial and 
use data from neuropsychological testing, patient and informant report, imaging, genetics, 
and other demographic and health information.  The most complex of these models is the 
Late-Life Dementia Risk Index (Barnes et al., 2009).  This index uses age, cognition 
(scores on two short screens), body mass index, ApoE4, imaging, vascular risk factors, 
functional abilities, and factors related to lifestyle to generate placement in three groups: 
low-risk (index score of 0-3), moderate-risk (index score of 4-7), and high-risk (index 
score ≥8). Although models such as the Late-Life Dementia Risk Index exist, their 
utility is limited because in clinical practice it is extremely rare to have access to 
information about so many risk factors, and many steps would be needed to gain 
information for the average patient.  This demonstrates two needs:  (1) models need to be 
designed that target MCI patients instead of the general population, and (2) standardized 
criteria need to be developed that identify at risk patients so a conversion model can be 
applied.  However, to date no multifactorial conversion models of this type have been 
developed.   
 As can be seen from the Late-Life Dementia Risk Index, biomarker and imaging 
data are important parts of a comprehensive model designed to predict dementia risk.  
However, as noted earlier, research regarding biomarkers and imaging in relation to MCI 
is in its infancy.  For the current study the following biomarkers and types of imaging are 
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candidates for inclusion in a statistical model designed to predict conversion from MCI to 
AD: (1) Homocysteine is a non-protein amino acid and associated with AD in studies 
comparing autopsied patients with AD versus controls (reviewed in Frank et al., 2003).  
Increased homocysteine levels are associated with a four times greater risk for AD; (2) 
Oxidative/nitrative damage is associated with AD, and specific isoprostanes are elevated 
in the urine, blood, and CSF of AD patients.  Moreover, oxidative/nitrative damage is 
correlated with memory impairments, CSF tau levels, and the number of APOE4 alleles 
(Frank et al., 2003; Pratico et al., 2000; Pratico, Clark, Liun, Lee, & Trojanowski, 2002; 
Pratico, Uryu, Leight, Trojanoswki, & Lee, 2001; Pratico, V, Trojanowski, Rokach, & 
Fitzgerald, 1998; Reckess, 2003; Yao et al., 2003);  (3) Recent studies have shown that 
sulfatide (a major constituent of brain lipids) may be associated with AD (reviewed in 
Reckess, 2003).  Sulfatide decreases up to 93% in gray matter and 58% in white matter in 
MCI versus controls.  Furthermore, CSF sulfatide may differentiate non-demented 
individuals from those with very mild dementia; (4) Tau and Aβ (components of tangles 
and plaques, respectively) are the most commonly studied potential AD biomarkers.  CSF 
tau levels are associated with AD pathology (decreased in patients with AD), and CSF 
tau levels aid in the differential diagnosis of AD from other dementing disorders (Arai et 
al., 1998; Arai, Morikawa et al., 1997; Arai et al., 1995; Araiet al., 1997; Clark et al., 
2003; Frank et al., 2003; Reckess, 2003); (5) Using MRI images, it has been shown that 
neurodegeneration of the medial temporal region and specifically the left hippocampus 
can be used to predict conversion from MCI to dementia (Risacher et al., 2009); (6) 
Abnormal patterns of glucose use have been associated with AD.  Using PET images, it 
has been shown that reduced glucose in the limbic structures and in particular the 
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hippocampus is associated with MCI and subsequent conversion to dementia (reviewed 




RESEARCH QUESTIONS AND HYPOTHESES 
 
 The current study will address the following research questions: 
1. Can demographic factors be used to predict conversion from MCI to 
dementia? It is hypothesized the female gender and low education will yield the 
highest predictive values.   
2. Can neuropsychological testing be used to predict conversion from MCI to 
dementia? It is hypothesized Logical Memory – II will yield the highest predictive 
value of any measure.  
3. Can biomarkers collected from CSF, urine, or blood be used to predict 
conversion from MCI to dementia? It is hypothesized homocysteine levels will 
yield the highest predictive value.   
4. Can brain imaging be used to predict conversion from MCI to dementia? It 
is hypothesized hypometabolism in the hippocampal brain area will yield the 
highest predictive value.     
5. Can daily functioning be used to predict conversion from MCI to 
dementia? It is hypothesized performance on tests of neuropsychological 
functioning will be a better predictor of conversion than daily functioning.   
6. Can neuropsychiatric functioning be used to predict conversion from MCI 
to dementia? It is hypothesized depression will yield the highest predictive value 
of any behavioral abnormalities.   
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7. Can data from neuropsychological testing, demographic variables, 
biomarkers, brain imaging, daily functioning, and neuropsychiatric functioning  
be used to construct a statistical model that predicts conversion from MCI to 
dementia with a high level of accuracy? Furthermore, can this model be used to 
predict conversion from MCI to dementia better than predictions made from any 
single variable or variables from any factor groups (i.e., neuropsychological 
testing, demographic variables, biomarkers, and brain imaging)?   
8. What diagnostic criteria can be used to construct an optimal screening 
model? For example, does a 1.0 SD or 1.5 SD cutoff using age- and education-
adjusted scores on tests of neuropsychological functioning yield more acceptable 
inclusion rates in application of the screening model? Also, does using premorbid 
intelligence increase the psychometric properties of a screening model? Finally, 
does allowing for some minor difficulties with ADLs yield a more optimal 
screening model?  It is hypothesized that using a 1.0 SD cutoff will be preferable 
to using a 1.5 SD cutoff, that taking premorbid intelligence into account will 
increase the psychometric properties of the screening model, and that allowing for 
some minor trouble with ADLs will further increase the psychometric properties 
of a screening model.   
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METHODS AND MATERIALS 
 
 Subjects 
 Data for the current study came from the publicly available portions of the 
Alzheimer’s disease Neuroimaging Initiative (ADNI).  The ADNI is a non-randomized, 
natural history non-treatment study of biological and neurocognitive factors in MCI.  In 
total, 800 subjects (200 normal controls, 400 MCI, and 200 mild AD) were recruited 
from 50 sites in the United States and Canada.  Subjects were between the ages of 55-90 
at the time of inclusion and required to provide an informant who could answer questions 
about the subject’s general functioning.  All subjects were required to consent to all test 
procedures and agree to longitudinal follow-up.  No subjects were included who were 
currently taking psychoactive medications.  The conversion from normal to MCI or AD 
and conversion from MCI to AD is of considerable interest.  ADNI researchers estimate 
the most frequent conversion will be from MCI to AD and will occur at approximately 
10-15% per annum.  
 For ADNI criteria, normal controls were required to score between 24-30 on the 
MMSE, have a Clinical Dementia Rating (CDR) score of 0, and be non-depressed.  MCI 
subjects were required to score between 24-30 on the MMSE, have a history of a memory 
complaint (from the subject or informant), fall below education-adjusted cutoff scores on 
the Logical Memory II subscale from the Wechsler Memory Scale – Revised (≤8 for 16 
or more years of education, ≤4 for 8-15 years of education, and ≤2 for 0-7 years of   
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education), have a CDR of 0.5, have no impairment in domains other than memory and 
essentially normal ADLs.  Mild AD subjects were required to have  a history of a 
memory complaint (from subject or study partner) and abnormal memory function as 
indicated by education adjusted cutoffs on the Logical Memory II subscale from the 
Wechsler Memory Scale – Revised (same cutoffs used for MCI), MMSE between 20 and 
26, CDR of 0.5 or 1.0. They also had to meet National Institute of Neurological and 
Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders 
Association (NINCDS/ADRDA) criteria for probable AD (McKhann et al., 1984). These 
criteria are as follows: memory impairment established by neuropsychological testing 
(using the standardized test battery), deficits (≤5th percentile using age- and education-
corrected scores) in two or more areas of cognition, evidence of continued decline from a 
previous level of functioning through a collateral source and structured clinical 
examination or assessment of activities of daily living, no disturbance of consciousness, 
onset between ages 40 and 90, and the absence of systemic disorders or other brain 
diseases that could account for the progressive deficits in memory and cognition.  These 
criteria have been shown to achieve good reliability and validity in the diagnosis of AD 
when compared with autopsy confirmed cases (Blacker et al., 1994).  
 To retain a high level of consistency between diagnostic categories, attempts were 
made to use ADNI criteria whenever possible. Consequently, the same cutoffs on the 
MMSE and CDR were used across diagnostic category. Four distinct samples were 
utilized for this study: patients identified as MCI using ADNI criteria, patients identified 
as MCI according to a 1.0 SD cutoff on Logical Memory Delayed and <6 on the FAQ 
(proposed criteria #1), patients identified as MCI according to a 1.5 SD cutoff on Logical 
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Memory Delayed and <6 on the FAQ (proposed criteria #2), and patients identified as 
MCI using a 1.5 SD cutoff in relation to VIQ and <6 on the FAQ (proposed criteria #3). 
Criteria used for each diagnostic classification system can be found in Table 7.  
 Procedures 
 After baseline visits were complete, an experienced neurologist or psychiatrist 
determined the best diagnosis (normal, MCI, AD, or other).  The diagnosing  
physician reviewed the medical history and all information gathered at the baseline visits 
to determine if there was significant impairment or deterioration.  Based on the results of 
the clinical, neuropsychological, and laboratory information, the physician may have 
made a diagnosis and, if appropriate, further classified the diagnosis of AD into Probable 
AD or Possible AD. For the purposes of the ADNI database, Possible AD refers to 
situations where a second disorder is present that may cause dementia but is not 
considered to be the primary cause of the dementia (i.e. AD is considered to be the 
primary cause).  If the subject had developed another diagnosis other than AD which is 
believed to be the primary etiology for cognitive impairment or dementia, this was also 
be specified.    
 At baseline, subjects underwent clinical and cognitive assessments.  Structural 
magnetic resonance imaging (1.5T MRI) was conducted at designated intervals for the 
length of study inclusion (2-3 years) for all subjects.  Approximately 50% of subjects also 
had Fluoro Deoxy Glucose Positron-Emission Tomography (FDG PET) scans at the same 
designated intervals.  An additional 25% of subjects were not scanned using PET had 
MRI at 3 Tesla for greater image resolution.  All subjects were evaluated at 0, 6, 12, and 
24 month intervals.  In addition, MCI subjects were evaluated at 18 and 36 months, and 
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normal controls were evaluated at 36 months.  IRB approval was obtained at all affiliated 
sites, and signed consent was required from all subjects and informants before inclusion.  
Further details about study procedures including pre-screening, data management, and 
quality control can be found online at 
http://www.adniinfo.org/Scientists/Pdfs/adni_protocol_9_19_08.pdf.   
 Demographic Variables of Interest 
 A number of studies have found education to protect people from developing 
dementia (Brayne et al., 2010; Del Ser et al., 1999; Letenneur et al., 1999; Ott et al., 
1995; Stern et al., 1994; Valenzuela et al., 2008; Valenzuela and Sachdev, 2006). Results 
of some studies indicate that females are more likely to develop dementia than males with 
gender differences becoming more pronounced for people over the age of 85 (Anderson 
et al., 1999; Brayne et al., 1995; Clark et al., 1996; Fratiglioni et al., 1997; Morgan et al., 
1993; Yoshitake et al., 1995).   
 Measure of Dementia Severity 
  Clinical Dementia Rating (CDR): 
The CDR (Berg, 1988) describes five degrees of impairment in performance on 
each of 6 categories: memory, orientation, judgment and problem solving, community 
affairs, home and hobbies, and personal care.  The ratings of degree of impairment 
obtained on each of the 6 categories of function are combined into one global rating of 
dementia (ranging from 0 to 3). The CDR has been shown to be reliable and valid for use 





 Measures of Neuropsychological Functioning 
  Mini-Mental State Examination (MMSE): 
The MMSE (Folstein et al., 1975) is a brief screening measure of general 
cognitive functioning and assesses the following cognitive domains: orientation, 
registration, short-term recall, attention, calculation, visuo/constructional skills and 
praxis.  Total scores range from 0-30.  Various cut-scores have been used to classify 
levels of cognitive impairment with scores ≤ 24 typically being indicative of cognitive 
impairment (Tombaugh & McIntyre, 1992).   Normative data correcting for age and 
education is also available (Crum et al., 1993).  Although demonstrating utility as a short 
screening measure for cognition (Clark et al., 1999), the MMSE is not an accurate stand-
alone measure for the diagnosis of AD (Tierney et al., 2000)  
  Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-COG): 
The ADAS-COG (Rosen, Mohs, & Davis, 1984) is a structured measure that 
evaluates the following domains: memory (word recall and word recognition), reasoning 
(following commands), language (naming and comprehension), orientation, ideational 
praxis (placing a letter into an envelope) and constructional praxis (copying geometric 
designs).  Ratings of spoken language, language comprehension, word finding difficulty, 
and ability to remember test instructions are also obtained.  The number of errors made 
determines overall test score (0-70).  Higher scores indicate greater impairment.    
  Logical Memory Test (Delayed Paragraph Recall): 
The Logical Memory test that was administered is a modification of the episodic 
memory measure from the Wechsler Memory Scale-Revised (WMS-R) (D Wechsler, 
1987).  Free recall of one short story (Story A) consisting of 25 bits of information was 
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recalled by the subject immediately after verbal presentation.  A delay condition of 30 
minutes is also included.   The total bits of information from the story that are recalled 
immediately (maximum score = 25) and after the delay interval (maximum score = 25) 
are recorded.  A retention or “savings” 
score can be computed by dividing the score achieved during delayed recall by the score 
achieved during immediate recall. 
  Boston Naming Test (BNT): 
The BNT (Kaplan, Goodglass, & Weintraub, 1983) is a measure of visual 
confrontational naming.  Subjects are required to name objects depicted in line drawings.  
For the ADNI, only 30 items were presented (either the odd- or even numbered items 
from the full 60-item test).  The drawings are graded in difficulty with the easiest 
drawings presented first.  If a subject encounters difficulty in naming an object, a 
stimulus/semantic cue (e.g., it is found in Egypt) and/or a phonemic cue (saying the first 
phonemes of the word) is provided.  The number of spontaneous correct responses 
(maximum score = 30) and spontaneous plus semantically-cued correct responses 
(maximum score = 30) are recorded.   
  Category Fluency: 
Category Fluency (Butters, Granholm, Salmon, Grant, & Wolfe, 1987) is a test of 
verbal fluency.  Subjects are instructed to generate as many examples as possible from 
each of two semantic categories (animals and vegetables) in a 60-second time period.  
Performance is measured by the number of correct, unique examples generated for the 
two categories.  Perseveration (repetitions of a correct item) and intrusion (non-category 
items) errors are also noted. 
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Clock Drawing Test: 
The Clock Drawing Test (Goodglass & Kaplan, 1983) is a test of 
visuoperceptual/construction skills and has two conditions: command and copy.  In the 
command condition, the subject is given a blank sheet of 8 1/2" X 11" paper and 
instructed to “Draw a clock, put in all of the numbers, and set the hands for 10 after 11.” 
After that task is completed, the subject is asked to copy a clock drawing.   A quantitative 
score (maximum total score = 10) is derived for each drawing by adding the scores of 
three separate features: 2 points for the integrity of the clock face, 4 points for the 
presence and sequencing of the numbers, and 4 points for the presence and placement of 
the hands.   The Clock Drawing Test is effective for discriminating between subjects with 
AD and normal elderly individuals (Cahn et al., 1996). 
  Digit Span:  
The Digit Span subtest from the WAIS-R (Wechsler, 1981) requires the subject to 
recall a series of single digits that were orally presented.  In the Forward condition, the 
subject must repeat the digits in the same order.  In the Backward condition, the digits 
must be repeated in the reverse order.  Testing is terminated when the subject misses both 
trials at a given sequence length.  A point is awarded for each correct sequence.  
Maximum score range is between 0-14.   
  Rey Auditory Verbal Learning Test (AVLT): 
The AVLT (Rey, 1964) is a test of learning and memory.  Fifteen unrelated nouns 




words on each trial is recorded.  Following a 20-minute delay, the subject is asked to 
recall as many of the 15 words as possible.  Directly following the delayed recall 
condition, a yes/no recognition test is administered.  The number of target “hits” and false 
positive responses are recorded.  Two equivalent alternate forms of the test were used 
across test sessions so that subjects were exposed to the same word list as infrequently as 
possible. 
  Trail Making Test:  
The Trail Making Test (Reitan, 1958) consists of two parts: Part A and Part B.  
For Part A the subject is instructed to connect 24 circles with a drawn line as quickly as 
possible in ascending numerical order.  For Part B, the subject is asked to connect the 
circles while alternating between numbers and letters in an ascending order (e.g., A to 1; 
1 to B; B to 2; 2 to C).  The subject's performance is judged in terms of time (in seconds) 
required to complete each trail and by the number of errors of commission and omission.  
The time to complete Part A (150 second maximum) and B (300 second maximum) will 
be the primary measures of interest.  Although both Parts A and B depend on visuomotor 
and perceptual-scanning skills, Part B also requires considerable cognitive flexibility in 
shifting from number to letter sets under time pressure.  Both parts of the Trail-Making 
Test are available in multiple forms of equal difficulty for purposes of repeated 
evaluation. 
  Digit Symbol Substitution:  
Digit Symbol Substitution (Wechsler, 1981) is a subtest from the WAIS-R that 
consists of 110 small blank squares (presented in seven rows), each randomly paired with 
one of nine numbers (1 to 9) printed directly above it.  Above the row of blank squares is 
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a printed “key” that pairs each of the numbers 1 through 9 with an unfamiliar symbol.  
Following a short series of practice trials, the subject must use the key to fill in the blank 
squares in order (working left to right across the rows) with the symbol that is paired with 
the number above it working as quickly as possible for 90 seconds.  The number of blank 
squares filled in correctly within the time limit is the measure of interest (maximum raw 
score = 110).  This test engages multiple cognitive abilities including attention, 
psychomotor speed, complex scanning, visual tracking, and immediate memory. 
Measure of Premorbid Intelligence 
  American National Adult Reading Test (ANART):  
The ANART (Nelson & O’Connell, 1978) is a test of reading used as an estimate 
of premorbid verbal intelligence.  For the ANART, patients are required to read and 
correctly pronounce 50 "irregular" words that do not follow common rules of 
phonography and orthography.  Consequently, correct pronunciation depends on previous 
familiarity with the word.  The 50 irregular words of the ANART are printed on a single 
sheet of paper which is presented to the subject who is instructed to read each word 
aloud.  The number of mispronounced words is recorded by the examiner (maximum 
errors = 50).  Premorbid verbal intelligence can be estimated by applying a formula 
derived by Grober and Sliwinski: (118.2 - .89 (AMNART errors) + .64 [years of 
education]) (Grober & Sliwinski, 1991). 
 Biomarkers 
Homocysteine is a non-protein amino acid implicated in AD.     
 Oxidative/nitrative damage is associated with AD and can be evaluated using the 
blood, urine, and CSF of patients.    
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 Sulfatides are important components in muscle and nerve cell membranes and 
have been implicated in AD.    
 Tau and Aβ are components of tangles and plaques, respectively and have been 
highly implicated in AD.   
Neuroimaging 
MRI scans use a large magnet, radio waves, antenna, and computer to produce 
clear images of the brain.  By using MRI, invasive methods such as X-rays can be 
bypassed.  Using MRI images, it has been shown that neurodegeneration of the medial 
temporal region and specifically the left hippocampus can be used to predict conversion 
from MCI to dementia (Risacher et al., 2009).    
 PET images can be used to detect how the brain uses glucose.  Abnormal patterns 
of glucose use have been associated with AD.   
 Measure of Functional Impairment 
  Functional Activities Questionnaire (FAQ): 
For the FAQ (Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982), a caregiver or 
qualified partner is asked to rate the subject’s ability to carry out ten complex ADLs: (1) 
manage finances, (2) complete forms, (3) shop, (4) perform games of skill or hobbies, (5) 
prepare hot beverages, (6) prepare a balanced meal, (7) follow current events, (8) attend 
to television programs, books or magazines, (9) remember appointments, and ((10) travel 
out of the neighborhood.  Each activity is rated as 0 (does without difficulty), 1 (needs 
frequent advice or assistance), or 2 (someone has taken over the activity).  Scores are 
summed across items to provide a total disability score (higher scores = greater 
impairment; maximum score = 20).  If an activity was never or very rarely performed 
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premorbidly, it is not rated and a pro-rated proportional score can be derived (achieved 
score / [20 – 2 times the number of items rated as never performed]). Using the FAQ, 
scores >5 have been shown to have predictive validity when distinguishing MCI from 
mild AD (Teng et al., 2010). 
 Measures of Emotional and Behavioral Functioning 
  Neuropsychiatric Inventory Q (NPIQ): 
The Neuropsychiatric Inventory (NPI) is used to assess both the frequency and 
severity of behavioral abnormalities across 10 domains: delusions, hallucinations, 
agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, and aberrant 
motor behavior.  Caregivers are asked to rate affected behaviors on a 1-4 scale for 
frequency (1 occasionally, 2 often, 3 frequently, and 4 very frequently) and a 1-3 scale 
for severity (1 mild, 2 moderate, 3 severe).  Each domain is calculated by multiplying 
frequency and severity.  NPI Total score (range = 0-12) is the product of the 10 domains 
designed to evaluate for behavioral abnormalities.  The NPIQ (Kaufer et al., 2000) is a 
shorter version that does only the screening questions and the severity rating for each 
domain.  The maximum score is 36. 
  Geriatric Depression Scale:  
The Geriatric Depression Scale (Short Form) (Sheikh & Yesavage, 1986) is a 
self-report measure of depression specifically designed for use with an older adult 
population.  The scale consists of 15 printed questions that the subject is asked to answer 
by circling yes or no on the basis of how he/she felt over the past week.  One point is 
given for each positive or negative answer that is indicative of a symptom of depression, 
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for a possible total of 15 points.  Total scores of 0-5 are considered normal, and scores of 
6-15 are considered evidence of clinically significant depression.   
 Statistical Analyses 
Statistical analyses were conducted using SPSS version 20.  For all models (see 
Table 7), four steps were carried out.  In the first step for all models, binary logistic 
regressions were conducted for each set of variables: (1) demographic factors (APOE 
included), (2) neurocognitive test scores, (3) biomarkers obtained from CSF, blood, and 
urine, and (4) MRI and PET imaging. Factors meeting a more liberal significance 
threshold of ≤0.1 for each class of variables were retained for the second step.  For the 
“hand selected” model, the second step consisted of factors being entered into a second 
binary logistic regression and then removed until an unsatisfactory reduction in 
Nagelkerke (or pseudo-R²) was noted.  For all other models, the second step consisted of 
remaining factors from each group being entered in a backward elimination binary 
logistic regression.  For the third step, scores for each patient were calculated using the 
resulting regression equation (i.e., (constant) + (variable score*β)).  Using the resulting 
scores on the regression equation, receiving operating characteristic plots (ROC) were 
calculated for each model.  Using ROC plots, sensitivity and specificity for each subject 
was obtained by taking sensitivity against 1-specificity (see Altman & Bland, 1994 for a 
detailed description of ROC plots).  For each model, the variable score is represented by 
the patient’s performance on that variable (e.g., Logical Memory II score, hippocampus 
volume, etc.).  These scores are then multiplied by the unstandardized beta weight for 
each variable obtained from conducting the regression.  Next, these values and the 
constant of the regression are summed into a single value that constitutes the predicted 
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score.  This score is then compared to the optimal cut-score that was obtained from the 
ROC analysis of the distribution of all predicted scores.  Next, the psychometric 
properties corresponding to each equation (i.e., sensitivity, specificity, negative predictive 
value, and positive predictive value) can be applied.  Finally, a probability can be given 
for the likelihood of converting to dementia.   
A separate set of binary logistic regressions were also conducted to determine the 
association between each resulting model to the diagnostic classification system from 
which it was derived as well as the association across classification systems.  
An independent sample t test was conducted to determine if daily functioning was 






Sample demographics for all patients identified as MCI according to all 
classification systems can be found in Table 8.   
Hypothesis #1: Can demographic factors be used to predict conversion from MCI to 
dementia? It is hypothesized that the female gender and low education will yield the 
highest predictive values. 
 No demographic variables were able to predict conversion from MCI to dementia 
at the .01 level (gender, B=.245, p=.137; education, B=-.008, p=.765; race, B=.042, 
p=.643; age, B<.001, p=.652) using ADNI diagnostic criteria.      
Hypothesis #2: Can neuropsychological testing be used to predict conversion from 
MCI to  
dementia? It is hypothesized Logical Memory – II will yield the highest predictive 
value of any measure.    
 Results of a backwards elimination regression using existing ADNI diagnostic 
criteria demonstrated that neuropsychological testing can be used to predict conversion 
from MCI to dementia with modest accuracy (pseudo R2 = .241, ROC = .823).   Using the 
optimal cutting score of -2.32, sensitivity of .80, and specificity of .71 was observed.   
For lower equation scores, sensitivity increased at the cost of specificity.   For higher 
equation scores, specificity increased at the cost of sensitivity.  Eleven variables were 
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retained in the final equation based on neurocognitive performance, and four were 
significant predictors at the .01 level (Table 9).  As expected, Logical Memory – II 
yielded the highest predictive value of any measure comprising the test battery (β=-.177, 
p<.001).   
Hypothesis #3: Can biomarkers collected from CSF, urine, or blood be used to 
predict conversion from MCI to dementia? It is hypothesized that homocysteine levels 
will yield the highest predictive value.    
 Results of a binary logistic regression show the only biomarker collected from 
CSF, urine, or blood to be a significant predictor of conversion was level of amyloid-beta 
(Abeta) 40 in plasma (β=-.017, p=.003) using ADNI diagnostic criteria.  Homocysteine 
was not a significant predictor of conversion (β=.014, p=.824).  The following 
biomarkers collected from CSF, urine or blood were also not significant predictors: 8-iso-
PGF2alpha isoprostane (β=.024, p=.814); 8,12-iso-iPF2alpha isoprostane (β=.054, 
p=.102); alpha-synuclein (β=.138, p=.681); CSF Tau level (β=-.007, p=.322); Abeta1-42 
(β=-.005, p=.322; pTau181p (β=.033, p=.192); and Abeta 42 (β=.036, p=.152).    
Hypothesis #4: Can brain imaging be used to predict conversion from MCI to 
dementia? It is hypothesized hypometabolism in the hippocampal brain area will 
yield the highest  
predictive value.    
 Results of a backwards elimination regression using existing ADNI diagnostic 
criteria demonstrated that brain imaging can be used to predict conversion from MCI to 
dementia with modest accuracy (pseudo R2=.371, ROC=.859).   Using the optimal cutting 
score of -2.04, predicted values generated by the equation achieved sensitivity of .85 and 
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specificity of .71.   For lower equation scores, sensitivity increased at the cost of 
specificity.   For higher scores, specificity increased at the cost of sensitivity.   Eleven 
variables were retained in the final equation based on brain imaging and seven were 
significant predictors at the .01 level (Table 10).  Cumulative temporal lobe atrophy 
yielded the highest predictive value of any imaging variable (β=-.063, p<.001).   
 Using ADNI criteria, the only PET variable that was a significant predictor at the 
.01 level was globally normalized cerebral metabolic rate for glucose (CMRgl) in the left 
mid temporal gyrus (β=-5.936, p=.01).   No PET variables were retained in the final 
imaging model.   
 In terms of laterality, remarkable consistency was found in the final neuroimaging 
model. For the right hemisphere, five brain structures were represented in the final model. 
For the left hemisphere, five brain structures were also represented in the final model.  
Hypothesis #5: Can ADLs and IADLs be used to predict conversion from MCI to 
dementia? It is hypothesized that performance on tests of neuropsychological 
functioning will be a better predictor of conversion than ADL performance.   
 FAQ total score (β=.123, p<.001) was a significant predictor at the .01 level using 
ADNI diagnostic criteria.  However, functional abilities were not retained in the final 
model, whereas, measures of delayed episodic memory were.  FAQ scores were 
significantly poorer for converters (mean 7.63, SD 5.6, range 0-28) than for 
nonconverters (mean 3.91, SD 4.6, range 0-27) at baseline (t[392]=-5.687, p<0.001).     
Hypothesis #6: Can neuropsychiatric functioning be used to predict conversion from 
MCI to  dementia? It is hypothesized depression will yield the highest predictive 
value of any  behavioral abnormality.   
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      Using ADNI criteria, no neuropsychiatric variable was a significant predictor at the 
.01 level: GDS (β=.205, p=.475) and NPI (β=.042, p=.800). 
Hypothesis #7: Can data from neuropsychological testing, demographic variables, 
biomarkers, brain imaging, ADLs, and neuropsychiatric functioning be used to 
construct a statistical model that predicts conversion from MCI to dementia with a 
high level of accuracy? Furthermore, can this model be used to predict conversion 
from MCI to dementia better than predictions made from any single variable or 
variables from any factor groups (i.e., neuropsychological testing, demographic 
variables, biomarkers, and brain imaging)?    
In total, 13 variables (see Table 11) were retained in the final model (pseudo R2=.61, 
ROC=.93) using the ADNI hand selected (see Statistical Analyses section) method 
(ADNI hand selected model).   A large proportion of variance was accounted for by the 
equation, and area under the curve was good.  Optimal cutting scores for predicted values 
generated by the equation achieved sensitivity of .94 and specificity of .79 for a positive 
predictive value of .66 and negative predictive value of .99.  For lower equation scores, 
sensitivity increased at the cost of specificity.  For higher equation scores, specificity 
increased at the cost of sensitivity.   
Hypothesis #8: What diagnostic criteria can be used to construct an optimal 
screening model? 
For example, does a 1.0 or 1.5 SD cutoff using age- and education-adjusted scores on 
tests of neuropsychological functioning yield more acceptable inclusion rates in 
application of the screening model? Also, does using premorbid intelligence increase 
the psychometric properties of a screening model? Finally, does allowing for some 
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minor difficulties with ADLs yield a more optimal screening model?  It is 
hypothesized that using a 1.0 SD cutoff will be preferable to using a 1.5 SD cutoff, 
that taking premorbid intelligence into account will increase the psychometric 
properties of the screening model, and that allowing for some minor trouble with 
ADLs will further increase the psychometric properties of a screening model.     
 The number and percentage of patients identified as normal, MCI, and mild AD 
using each classification system can be found in Table 12.   For each classification 
system, statistical models were constructed to predict conversion from MCI to dementia 
(see Table 7 for a detailed description of diagnostic criteria used for each classification 
system).   Two models were constructed for ADNI criteria using different methods: a 
backward elimination method (ADNI backward elimination model) and a hand selected 
method (ADNI hand selected model) (see the statistical analyses section for a detailed 
description of the methods used to construct these two models).  For the backward 
elimination model (Table 13), 11 variables were retained in the final model (pseudo 
R
2=.50, ROC=.91).   For the hand selected model (Table 11), 13 variables were retained 
in the final model (pseudo R2=.61, ROC=.93).   For Model #1 (Table 14), 23 variables 
were retained in the final model (pseudo R2=.74, ROC=.97).   For Model #2 (Table 15), 
12 variables were retained (pseudo R2=.77, ROC=.97) in the final model.   For Model #3 
(Table 16), 6 variables were retained (pseudo R2=.41, ROC=.88) in the final model.   
 Cutting scores for predicted values generated by each equation with sensitivity of 
.90 were associated with specificity of .80 for the ADNI hand selected model, specificity 
of .71 for the ADNI backward elimination model, specificity of .90 for proposed model 
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#1, specificity of .95 for proposed model #2, and specificity of .76 for proposed model 
#3.   
 Final equations for each model were compared across each diagnostic system (see 
Tables 17 and 18).   For example, how well does the ADNI hand selected model perform 
for patients identified as MCI using proposed criteria #1, and so on.   Table 17 lists the 
results of a series of binary logistic regressions.  As can be seen, with the exception of the 
ADNI backwards elimination model, each resulting model score was a significant 
predictor of conversion using the associated classification system.  For example, the 
ADNI hand selected model was a significant predictor of conversion using ADNI 
diagnostic criteria, model #1 was a significant predictor of conversion using proposed 
criteria #1, model #2 was a significant predictor of conversion using proposed criteria #2, 
and model #3 was a significant predictor of conversion using proposed criteria #3.  The 
only model that was a significant predictor at the .01 level across classification systems 
was Model #1.  It was a significant predictor using ADNI diagnostic criteria (β=6.032, 
p<.001) and using proposed criteria #3 (β=3.558, p=.002).  Model #1 trended towards 
significance using proposed criteria #2 (β=9.190, p=.051).  In Table 18, pseudo R2 and 
AUC was examined across diagnostic system.  Similar to the results listed in Table 17, 
Model #1 appears to be the best performing model across diagnostic classification 
systems.     
 When only allowing for “essentially normal” ADLs (defined as 0-1 on the FAQ), 
108 patients were classified as MCI at baseline.   Of these patients, 35 converted to 




Follow-Up Analyses:  
Evaluating CSF Homocysteine at the Univariate Level 
 Homocysteine CSF level was not predictive of conversion from MCI to dementia 
(β=.041, p=0.134).   
Constructing the Most User-Friendly Equation for Neuropsychologists 
 For this model, only raw scores for major neurocognitive indices (e.g., AVLT 
Total, BNT Total, etc.) and daily functioning were used.  In total, six variables were 
retained in the final model (see Table 19).  A pseudo R2 of .22 and ROC of .81 were 
observed.  The optimal cutting score of -3.32 achieved sensitivity of .82 and specificity of 
.68.  For lower equation scores, sensitivity increased at the cost of specificity.  For higher 





 In the current study, diagnostic criteria for MCI and the ability of factors from 
several categories (i.e., demographic, neurocognitive, functioning, imaging, biomarker, 
and behavioral) to predict conversion from MCI to dementia were examined.  Although 
having been significantly transformed since their inception, it was demonstrated through 
a review of the literature that current MCI diagnostic criteria are limited.  First, as 
currently written, these criteria are reliant on human judgment.  However, human 
judgment is subject to numerous factors that compromise its efficacy (Wedding & Faust, 
1989) and render it suboptimal to judgments based on equations derived from statistical 
analyses (Dawes, 2005; Dawes, Faust, & Meehl, 1989; Garb, 1994; Goldberg, 1965; 
Goldberg, 1968; Goldberg, 1970; Grove et al., 2000; Marchese, 1992; Meehl, 1954; 
Meehl, 1984; Sines, 1971; Wiggins, 1981).  Second, multiple diagnostic criteria are 
available so different criteria are being used by different clinicians.  Third, as currently 
written, all available criteria are somewhat ambiguous and can be applied in different 
ways.  For example, whereas one clinician judges impairment to be 1.5 SD below the 
mean, another clinician may judge impairment to be 1.0 SD below the mean.  
Consequently, error variance is introduced and has led to widely varying estimates of 
incidence, prevalence, and conversion.   
  Although eight hypotheses were explored in the current study, each of the first six 
hypotheses were constructed to lead up to the final two overarching hypotheses: MCI   
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diagnostic criteria can be modified in a manner that removes much of the necessity of 
using human judgment and a statistical equation can be constructed to predict conversion 
from MCI to dementia with a high degree of accuracy.  Results of the current study 
supported these two hypotheses.  First, it was demonstrated that MCI diagnostic criteria 
could be modified in a manner that lessens the reliance on human judgment but also 
enhances the ease with which MCI diagnostic criteria can be utilized and applied.  
Second, it was demonstrated that an equation could be constructed using regression 
modeling that predicts conversion from MCI to dementia with a high degree of accuracy.  
Although this finding was consistent across varying applications of diagnostic criteria, 
the model that demonstrated the best level of predictive power was the model using (1) 
intact general cognitive functioning, (2) a 1.0 SD cutoff on one or more cognitive 
domains, and (3) an allowance for some level of functional impairment.  This finding was 
consistent with a priori expectations.    
 For MCI to truly represent its conceptual base—as a predementia syndrome with 
an etiology commensurate to dementia—the diagnostic criteria should be constructed in 
such a way that a high number of people diagnosed with MCI go on to develop dementia.  
In this paper, an attempt was made to redefine the diagnostic criteria currently available 
for MCI.  However, the two overarching hypotheses are composed of variables 
representing a number of different classes (i.e., demographic, neurocognitive, functional, 
imaging, biomarker, and behavioral variables), and each of these parts is represented by 
the other six research hypotheses.  In the sections that follow, each of these parts (i.e., 
“building-block” hypotheses) will be discussed with rationale pertaining to the reasoning 
behind the hypothesis formulation.  In ADL and IADL performance, for example, a priori 
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expectations stated that both a screening and conversion model would be aided by aspects 
of functional ability.  Thus, daily functioning was expected to be a variable with a unique 
contribution to conversion when examined in isolation from variables in other categories 
and also to combine with variables from other categories to make an effective prediction 
model.  Thus, these parts or “building-block” hypotheses (e.g., functional ability) were 
analyzed in a step-by-step fashion and used to build-up to the two overarching 
hypotheses.  Without including these “building-block” steps as a point of reference, the 
main points (i.e., overarching hypotheses) could not be fully discussed.  In the sections 
that follow, each of the eight hypotheses evaluated in this paper will be discussed.  The 
final two hypotheses reflecting the two main points of this study will be discussed in 
terms of their contributing parts or building-blocks.  A discussion of the limitations of 
this study and potential future directions of research will follow.  Finally, clinical and 
research implications of the findings outlined in this study will be discussed and followed 
by a brief conclusion.   
Hypothesis #1: Can demographic factors be used to predict conversion from MCI to 
dementia? It is hypothesized that the female gender and low education will yield the 
highest predictive values. 
 Education 
 It was expected in the current study that education would serve as a protective 
factor from conversion.  Contrary to this expectation, however, education was not 
observed to protect a person with MCI from converting to dementia.  These results seem 
to indicate that once domain specific impairment is present education no longer functions 
as a protective factor.   These results also indicate that with a threshold of cognitive 
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impairment education no longer protects against future general cognitive impairment 
and/or functional impairment.  One of two explanations seems likely.  First, once a 
person is impaired in at least one cognitive domain, the mitigating aspects of a cognitive 
reserve are all but extinguished.  Thus, domain specific impairment renders the protective 
qualities of education inert regardless of level of education.  Second, to be classified as 
exhibiting domain specific impairment, a person with a high level of education is already 
more impaired than a person with a low level of education and already utilizing 
considerable cognitive reserve to not be considered demented.  Thus, whatever higher 
level of reserve was present has now been exhausted or almost exhausted.  Exploring the 
validity of these two explanations was beyond the scope of this study. However, the 
incorporation of previous research results into the framework offered by the current study 
may offer some clues.    
            The bulk of studies available in the literature examine the protective factors of 
education as they relate to a healthy older adult eventually developing dementia (Brayne 
et al., 2010; Del Ser et al., 1999; Letenneur et al., 1999; Ott et al., 1995; Stern et al., 
1994; Valenzuela et al., 2008; Valenzuela and Sachdev, 2006), but conversion is not 
development.  For development studies, a person is recruited as a healthy older adult and 
followed until he/she is diagnosed with dementia.  In this scenario, an unbroken timeline 
is present from relative good cognitive health to cognitive and functional impairment 
characteristic of dementia.  Thus, without a point of reference in the timeline, education 
could be functioning as a protective factor from any aspect of dementia including domain 
specific cognitive impairment, general cognitive impairment, functional decline, or all 
three.  For conversion, on the other hand, some level of domain specific cognitive 
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impairment has already occurred, thereby, inserting a reference point in the timeline of 
normal cognition to development of dementia.  Thus, only general cognitive impairment 
and functional decline are left as possible factors from which education could serve as a 
protective factor.     
  In contrast to the finding outlined above that states education does not protect a 
person with MCI from converting to dementia, the results of numerous longitudinal 
studies have indicated that education is a protective factor against developing dementia 
(Letenneur et al., 1999; Ott et al., 1995; Stern et al., 1994).  The exact mechanism for this 
protection is unknown and two different hypotheses have been proposed.  In one 
hypothesis, education is thought to protect the brain from the underlying pathologies 
associated with dementia (Del Ser et al., 1999).  In the alternate hypothesis, people with 
more education are thought to have a better capacity to compensate for the neuropathic 
changes associated with dementia (Valenzuela et al., 2008; Valenzuela and Sachdev, 
2006).  In other words, people with more education will have brain atrophy comparable 
to people with less education but will be better able to compensate for this atrophy 
because of a greater cognitive reserve.   
  In an attempt to better characterize the mechanism that education has on dementia 
acquisition, Brayne and colleagues (2010) examined the association between education 
and brain pathology at death.  Results indicated that although associated with decreased 
dementia risk and greater brain weight, education was not associated with a decrease in 
neuropathology.  Thus, education did not protect people from atrophy but did mitigate the 
clinical expression of dementia.  Regardless of the mechanism of protection, the more 
education a person had the less likely he/she was to develop dementia.  However, in 
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contrast to expectations, the results of the current study indicated that this trend does not 
hold for people already exhibiting cognitive impairment characteristic of MCI, thereby, 
supporting the notion that domain specific impairment exhausts the protective aspects of 
education.   
  Gender 
  Although controversy exists about overall gender difference in dementia 
development, rates of AD are higher among females than among males at some point in 
the aging process.  Given that aMCI patients were included in the ADNI database 
combined with knowledge that women have a greater risk of developing AD, it was 
hypothesized that females would convert at a higher rate than males.  However, this 
assumption was not supported by the results of the current study, and rates of conversion 
did not differ significantly between females and males.  The likely explanations for this 
finding are identical to the reasons given for the lack of an effect of education.  Namely, 
the point of interest in the timeline is actually mild cognitive impairment as opposed to 
dementia.  However, sample specific factors may also be contributing which include age 
of the sample (mean of 75 years) and the inclusion of almost twice as many males than 
females.    
 In regards to any dementia type, previous studies on incidence rates in males and 
females are mixed.  Results of some studies indicate that females are more likely to 
develop dementia than males with gender differences becoming more pronounced for 
people over the age of 85 (Anderson et al., 1999; Brayne et al., 1995; Clark et al., 1996; 
Fratiglioni et al., 1997; Morgan et al., 1993; Yoshitake et al., 1995).  But results of other 
studies have noted a lack of significantly different incidence rates of dementia between 
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females and males (Bachman et al., 1993; Ganguli et al., 2000; Letenneur et al., 1994; 
Paykel et al., 1994; Rocca et al., 1998).  In contrast to conversion to any dementia type, 
the focus of the current study was conversion specifically to AD.  In the AD literature, 
results consistently note that development becomes more prevalent in females than in 
males at some point during the aging process (Brayne et al., 1995; Fratiglioni et al., 1997; 
Hagnell, Ojesjo, & Rorsman, 1992; Letenneur et al., 1994).  Thus, it was expected that 
this trend would extend from development to conversion.  However, as noted above, this 
expectation was not found.     
Hypothesis #2: Can neuropsychological testing be used to predict conversion from 
MCI to  
dementia? It is hypothesized Logical Memory – II will yield the highest predictive 
value of any measure.    
In the current study, an evaluation of neurocognitive results indicated that four 
variables were significant predictors of conversion when analyzed in combination with 
all other neuropsychological variables (see Table 10).  As can be seen, all of these 
variables relate to three cognitive domains: (delayed) memory, language, and processing 
speed.  Next, using only neuropsychological variables, an equation was constructed to 
identify people with MCI who would eventually convert to dementia.  The resulting 
model accounted for roughly a quarter of variance.  Moreover, its associated clinical 
cutoff may provide clinicians with a useful tool when questions about conversion arise.  
Using only a person’s neurocognitive profile, the resulting equation predicted conversion 
from MCI to AD with modest accuracy.  As expected, a test of delayed episodic memory 
(i.e., Logical Memory – II) exhibited the highest predictive power of any 
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neuropsychological variable.  Other measures of episodic memory as well as measures of 
recognition memory, executive functioning, language, attention, and processing speed 
were also retained in the final model (Table 9).  The optimal cut-score for this equation 
was noted as obtaining sensitivity of 80% and specificity of 71%.  The equation along 
with examples of using the equation can be found in Table 9 and Appendix #1.  In 
addition, an Excel spreadsheet and detailed instructions for working this equation can be 
obtained from the first author of this study.    
 Like in the current study, the association between conversion from MCI to AD 
and neuropsychological variables has previously been examined.  Consistent with the 
results of this study, results of prior studies show that neurocognitive functioning is a 
significant predictor and that memory impairment is the most powerful univariate 
predictor of conversion from MCI to AD (Aggarwal et al., 2005; Blacker et al., 2007; 
Devanand et al., 2008; Gomar et al., 2011; Tabert et al., 2006; Tierney et al., 1996).  
Impairments in executive functioning (Blacker et al., 2007; Gomar et al., 2011; Tabert et 
al., 2006; Tierney et al., 1996) and processing speed (Aggarwal et al., 2005; Gomar et al., 
2011) have also been shown to significantly increase conversion risk.  These results fit 
well with the results outlined in the current study.  In addition, older adults with impaired 
memory as well as impaired functioning in at least one other cognitive domain are shown 
to be more at risk of conversion over a three-year period (Tabert et al., 2006).  These 
findings also assimilate well with the results of the current study which demonstrated that 
impairment in three cognitive domains (i.e., episodic memory, language, and processing 
speed) was particularly predictive of conversion over a one-year period.  However, the 
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model and resulting equation offered in the current work expand upon these findings and 
present the opportunity for enhanced clinical utility.    
 Regression models have been detailed prior to the current study.  Moreover, like 
in the current study, regression models have been utilized to determine the ability of 
numerous neuropsychological variables to predict conversion.  In a sample of 218 older 
adults diagnosed with MCI, measures of episodic memory, semantic memory, working 
memory, and processing speed were all noted as univariate predictors of conversion 
(Aggarwal et al., 2005) with performance on a measure of visuospatial ability not being 
associated with conversion.  When all variables were analyzed together, only episodic 
memory and processing speed remained significant predictors with episodic memory the 
strongest predictor at both the univariate and multivariate level.  Older adults with poorer 
episodic memory were twice as likely to convert when compared with older adults who 
have diminished performance in another cognitive domain.  Moreover, poorer baseline 
episodic memory was predictive of a more rapid overall decline and an increased risk of 
conversion over a 10-year period.  A decline in a cognitive domain other than memory 
was only predictive of conversion for the year immediately following onset of single-
domain impairment.  Executive functioning (Blacker et al., 2007; Tabert et al., 2007; 
Tierney et al., 1996) has also been observed to significantly predict conversion and when 
combined with performance on a measure of delayed visual memory has been noted as 
achieving sensitivity of 76% and specificity of 94% (Tierney et al., 1996).  Although 
these findings add to the research literature and are useful in a clinical context, the ability 
of clinicians to apply this information is limited.  Thus, the detailing of a statistical model 
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in the present work offers an exciting expansion of regression models for the prediction 
of conversion from MCI to dementia.      
Hypothesis #3: Can biomarkers collected from CSF, urine, or blood be used to 
predict conversion from MCI to dementia? It is hypothesized that homocysteine levels 
will yield the highest predictive value. 
 The term “biomarker” refers to entities that are associated with a disease through 
concentration, presence, and activity (Anoop, Singh, Jacob & Maji, 2010).  In the current 
study, the only biomarker collected from CSF, urine, and blood/plasma to be a significant 
predictor of conversion was Aβ40.  Aβ or amyloid-beta is a term used to describe 
peptides of 36-43 amino acids.  Aβ40 has been shown to be present in both senile plaques 
as well as vascular amyloid and both senile plaques and vascular amyloid are hallmarks 
of dementia (Castano et al., 1996).  Therefore, given the association senile plaques and 
vascular amyloid have with dementia and AD (Castano et al., 1996), it is not surprising 
that some form of amyloid-beta was able to predict conversion from aMCI to AD.   
 In contrast to a priori expectations, homocysteine CSF level was not significantly 
related to conversion.  A potential reason that a discrepancy exists between the findings 
of the current study and those noted by Mattsson and colleagues (2009) is that AD 
biomarkers in the latter study were examined at the univariate level.  Thus, homocysteine 
CSF level was analyzed at the univariate level for a follow-up analysis in the current 
study.  Once again, findings were contrary to those by Mattsson and colleagues (2009), 
and homocysteine CSF levels were not predictive of conversion even when analyzed in 
isolation.  As noted by Jack et al.  (2010) a possible reason for the above mentioned 
discrepancy may be one of timing because different biomarkers may have different 
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predictive values at varying times in the progression of a disease.  For example, in MCI, 
progression during the first year may be highly associated with baseline markers of 
neurodegeneration.  However, progression may be better accounted for by markers of 
brain amyloid over a longer longitudinal course (Dickerson & Wolk, 2013).      
Earlier in this paper, a brief review of CSF, urine, and blood biomarkers in AD 
was conducted.  As was evident in this review, most statistically relevant AD biomarkers 
have been discovered in CSF as opposed to urine and blood/plasma.  Thus, studies have 
also been conducted to determine if the examination of CSF for conversion biomarkers is 
useful.  However, most of these studies included small samples examined only at a single 
site.  In a large-scale study of 750 MCI patients in 12 centers located in the United States 
and Europe, the ability of CSF biomarkers to predict incipient AD in patients with MCI 
(Mattsson et al., 2009).  Results indicated that three CSF biomarkers (i.e., Aβ42, P-Tau, 
and T-Tau) could be used to predict conversion with good accuracy.  Less accuracy was 
reported in studies utilizing smaller samples examined at a single site.  The authors also 
noted that some of the variability in the literature is present because the procedures used 
for designating biomarker cutoffs as well as the cutoffs themselves varied considerably 
from study to study.  Thus, optimal clinical cut-scores have yet to be established for 
biomarker data and clinical judgment appears to be an issue in the study of these 
variables.  Regardless, given that biomarkers of conversion were noted in a large-scale 
study, it was expected that the current results would fundamentally match these earlier 
findings.  However, this expectation was not met.       
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Hypothesis #4: Can brain imaging be used to predict conversion from MCI to 
dementia? It is hypothesized hypometabolism in the hippocampal brain area will 
yield the highest  
predictive value.    
 In the current study, an evaluation of MRI results indicated that six areas were 
significant predictors of conversion when analyzed in combination with all other MRI 
variables: cumulative temporal lobe atrophy, left hippocampal volume, right precentral 
cortex volume, right middle orbital grey matter volume, right posterior cingulum grey 
matter volume, left superior temporal gyrus volume, and right cerebellum grey matter 
volume (see Table 10).  As expected, with the exception of right cerebellum grey matter 
volume and right posterior cingulum volume, all of these areas are located in the frontal 
or temporal lobes and consistent with previous imaging studies evaluating conversion 
from MCI to dementia (Devanand et al., 2007; Whitwell et al., 2008).    
For PET, only glucose consumption in the left middle temporal gyrus was a 
significant predictor of conversion when analyzed in combination with all other PET 
variables.  However, this variable was not retained in the final imaging model.  Contrary 
to a priori hypotheses, reduced glucose consumption in the hippocampus was not the 
strongest imaging predictor.  In this sample, cumulative temporal lobe atrophy exhibited 
the greatest predictive value when compared to PET and MRI variables.    
Next, an equation was constructed to identify people with MCI that would convert 
to dementia using only imaging variables.  This model accounted for approximately a 
third of variance in conversion, and the resulting equation (see Table 10) predicted 
conversion from MCI to AD with modest accuracy.  The optimal cut-score for this 
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equation (-2.04) was noted as obtaining sensitivity of 85% and specificity of 71% via 
ROC analysis.  The equation along with examples of using the equation can be found in 
Table 10 and Appendix #2.  In addition, an Excel spreadsheet and detailed instructions 
for working this equation can be obtained from the first author of this study.    
 As in the current study, the utility of using imaging results to predict conversion 
in MCI patients has previously been examined.  In one such study, 139 people with MCI 
and 63 healthy controls were scanned using MRI and followed for five years (Devanand 
et al., 2007).  Consistent with the results of the current study, temporal structures could 
be used to classify sample groups.  At baseline, Devanand and colleagues (2007) noted 
that hippocampal and entorhinal cortex volumes were largest in healthy controls, 
intermediate in nonconverters, and smallest in converters.  Relative volumes of these 
same brain areas were also found to significantly predict time to conversion.  In another 
study, 63 people with aMCI and 63 demographically matched controls were scanned 
using MRI and followed for three years (Whitwell et al., 2008).  When compared to 
controls, MCI patients that converted to dementia had bilateral loss affecting the medial 
and inferior temporal lobe, the temporoparietal association cortex, and the frontal lobes.  
When compared to nonconverters, MCI patients that converted to dementia had MRI 
profiles strikingly similar to those of the current study.  Also in the study by Whitwell 
and colleagues (2008), greater loss was noted in the medial and inferior temporal lobes, 
the temporoparietal cortex, the posterior cingulate, the precuneus, the anterior cingulate, 
and the frontal lobes.   
 In contrast to MRI, FDG-PET studies in MCI are controversial because reduced 
cerebral metabolic rate of glucose consumption may not be detectable outside the 
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hippocampal formation in patients with minimal impairment (Schuff & Zhu, 2007).  
However, in a small PET study, cortical changes to glucose metabolism were observed in 
a group of MCI patients that were scanned twice over a year (Drzezga et al., 2003).  
Glucose consumption was lower in the posterior cingulate cortex and precuneus for 
converters than it was for nonconverters at baseline.  At follow-up, glucose consumption 
was lower in bilateral prefrontal areas, and reduced consumption had progressed in the 
posterior cingulate cortex.  This finding was not supported by the results of the current 
study since only hypometabolism in the left middle temporal gyrus was predictive of 
conversion at the .01 level. 
Hypothesis #5: Can daily functioning be used to predict conversion from MCI to 
dementia? It is hypothesized that performance on tests of neuropsychological 
functioning will be a better predictor of conversion than daily functioning.   
Consistent with a priori expectations, functional abilities significantly predicted 
conversion.  Interestingly, although functional abilities were poorer for converters at 
baseline, nonconverters also demonstrated multiple functional decrements even when 
utilizing the FAQ—a means of evaluation less objective than a performance-based 
measure.  Thus, it not only appears that functional impairment is a characteristic of MCI, 
but it also appears that a continuum exists between MCI and dementia in regards to 
functional impairment.  Also consistent with prior expectations, delayed episodic 
memory was a stronger univariate predictor of conversion than functional ability.       
 Prior research has shown that although basic ADLs (i.e., eating, dressing, bathing, 
etc.) remain preserved in people with mild cognitive impairments, higher-order IADLs 
(i.e., financial and medication management, using public transportation, interacting with 
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technology, etc.) are often subtly impaired (Winblad et al., 2004).  But as highlighted 
earlier, diagnostic criteria related to everyday functioning in MCI are (see Tables 1 and 3) 
constructed in a manner that assumes delineation between virtually intact functional 
abilities for MCI and impaired functional abilities for dementia.  However, the results of 
this study do not support this delineation as both converters and nonconverters presented 
with functional decrements.  In addition, prior research also points to this delineation as 
problematic for a number of reasons (Goldberg et al., 2010).  First, medical and 
psychiatric conditions that are reliably associated with cognitive changes are, in turn, also 
reliably associated with changes in everyday functioning (Goldberg et al., 1990; Heaton 
et al., 1994).  Second, given that cognitive decline is associated with changes in everyday 
functioning, the cognitive impairments characteristic of MCI should exact a graduated 
cost on function (Goldberg et al., 2010). 
 In addition to issues with the current diagnostic criteria, the evaluation of daily 
functioning in MCI is flawed because standardized measures sensitive to minor 
functional changes are not commonly utilized (Goldberg et al., 2010).  At present, the 
most common method for garnering information about the everyday functioning of a 
patient is to interview a close relative.  However, the reliability of this method suffers 
because of halo effects, memory lapses, and limited knowledge that can lead to an 
overestimation of the functional capacity of MCI patients (Loewenstein et al., 2001).  
One way to increase the utility of functional evaluations would be to introduce the use of 
performance-based measures into standard neuropsychological test batteries.  Recent 
research has demonstrated that patients with MCI show significantly compromised 
functional abilities when evaluated with performance-based measures, and this trend 
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extends to patients identified as having intact functioning by family members (Goldberg 
et al., 2010).   
 Unfortunately, performance-based measures were not utilized as part of the ADNI 
study.  However, the measure utilized in ADNI (i.e., FAQ) was designed to evaluate a 
number of higher-order IADLs and produce a total score that can be compared between 
patients.  Given that patients with MCI likely demonstrate functional impairment on a 
continuum with dementia, it was assumed that differences would be present and 
statistically discernable among patients  
who convert to dementia and patients who do not convert to dementia.  This expectation 
was supported by the findings of this study.      
Hypothesis #6: Can neuropsychiatric functioning be used to predict conversion from 
MCI to dementia? It is hypothesized that depression will yield the highest predictive 
value of any behavioral abnormality.   
Contrary to expectations, results of the current study showed that depression was 
not predictive of conversion to dementia in this sample of people with MCI.  Of all 
psychiatric conditions, depression’s relationship with cognitive impairment is by far the 
most widely studied and discussed.  Up to 50% of all people living with AD have 
significant symptoms of depression and up to 20% meet diagnostic criteria for major 
depression (Wragg & Jeste, 1989).  Although results of a meta-analysis demonstrate that 
depression is a risk factor for dementia (Jorm, 2001), some studies have not noted an 
association between depression and dementia (Becker et al., 2009; Fassbender et al., 
1999; Hendersen et al., 1997).  Moreover, the role of depression as a risk for dementia is 
not well understood, and multiple hypotheses explaining the association are found in the 
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literature (Jorm, 2001).  These hypotheses include: (1) depression is an early prodome of 
dementia, (2) depression brings forward the clinical aspects of dementia, and (3) 
depression leads to hippocampal damage.   
The expectation that depression would be predictive of conversion was made 
despite its contradiction to an earlier study by Panza and colleagues (2008) that found no 
association between depression and conversion in a sample of 2,963 community-dwelling 
adults between the ages of 65-84 who were followed for 3.5 years.  Moreover, results 
also showed that no socio-demographic or vascular risk factors could be used to modify 
the association between depression and conversion.  However, in a more homogenous 
sample that utilized hospital patients, depression was able to predict conversion from 
MCI to dementia (Modrego and Ferrandez, 2004).  The reason it was hypothesized that 
results of the current study would more closely match the findings of Modrego and 
Ferrandez (2004) than the findings of Panza et al.  (2008) were twofold.  First, in the 
2008 study by Panza and colleagues, only 10% of the sample of people with MCI 
converted to dementia.  Thus, it was believed that the sample likely represented a group 
of MCI patients more cognitively advanced than normal.  Second, it was believed that the 
sample of hospital patients utilized by Modrego and Ferrandez (2004) would likely 
represent a group of people with more cognitive impairments and higher rates of 
depression than the people included in the ADNI sample.   
As documented earlier, results of a meta-analysis noted that depression is a 
significant risk factor of dementia development (Jorm, 2001).  Interestingly, current study 
findings are in contrast to this association and seem to indicate that this risk is minimized 
once cognitive impairment is present.  The most likely reason for this dissociation is that 
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studies of dementia development follow healthy controls with normal cognitive 
functioning while studies of conversion follow adults with some level of cognitive 
impairment.  Thus, the current results and findings of Panza and colleagues (2008) seem 
to indicate that depression is a risk factor for dementia simply because it is a risk factor 
for cognitive impairment.  In addition, these results may indicate that the presence of 
significant cognitive impairment dulls the additive effects of factors with lesser 
associations to dementia development (e.g., gender, education, depression).   However, 
the investigation of this theory is beyond the scope of this study.  Other potential reasons 
to explain the lack of association between conversion and depression relate to the ADNI 
sample itself, namely, that levels of depression were low in the ADNI sample, that the 
use of a self-report measure of depression lacked sensitivity, that follow-up was limited 
to 2-years, and that some people with depressive symptoms were receiving treatment for 
depressive symptoms.      
 Hypothesis #7: Can data from neuropsychological testing, demographic variables, 
biomarkers, brain imaging, ADLs, and neuropsychiatric functioning be used to 
construct a statistical model that predicts conversion from MCI to dementia with a 
high level of accuracy? Furthermore, can this model be used to predict conversion 
from MCI to dementia better than predictions made from any single variable or 
variables from any factor groups (i.e., neuropsychological testing, demographic 
variables, biomarkers, and brain imaging)? 
In the current study, the following variables were significant predictors of 
conversion when all categories of variables were taken into account (Table 11): AVLT 
Total Intrusions for Trial 2, BNT Total semantic cues, cumulative temporal lobe atrophy, 
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right precentral grey matter, and right front mid orbital grey matter.  The resulting 
equation accounted for approximately two-thirds of variance and predicted conversion 
from MCI to AD with a high level of accuracy.  Moreover, this model was able to predict 
conversion from MCI to dementia better than predictions made from any single variable 
or variables from any factor groups.  The optimal cut-score for this equation (-2.11) was 
noted as obtaining sensitivity of 94% and specificity of 79% for a positive predictive 
value of 66% and negative predictive value of 99%.  For people scoring above the 
clinical cut-score of -2.11, the predictive value obtained from the equation indicated a 
high risk of converting to dementia over the course of the following year, and this was 
correct 66% of the time.  For people scoring below or equal to -2.11, the value obtained 
from the equation indicated a lower risk of conversion over the next year, and this was 
correct 99% of the time.  Examples of this regression-based model are provided in Table 
11, and a guide for operating these types of equations can be found in the appendix.  
Moreover, an Excel spreadsheet and instructions can be obtained from the first author of 
this study that will aid in working the predictive equation.   
 To date, only a handful of studies have examined factors spanning a number of 
different categories (e.g., demographics, biomarkers, imaging, and cognition) in 
predicting conversion from MCI to dementia.  In the first study of its kind, Jack and 
colleagues (1999) followed 80 patients diagnosed with MCI for an average of 
approximately 32 months.  All 80 patients received an MRI of the head at baseline and 
other testing.   Of the 80 patients included in the sample, 27 converted to dementia.  The 
factor most capable of predicting conversion at the univariate level was baseline 
hippocampal atrophy.  Moreover, the addition of age, postmenopausal estrogen 
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replacement, cognition (i.e., general cognitive functioning, verbal memory, attention, and 
verbal fluency), APOE, history of ischemic heart disease, and hypertension did not 
significantly increase the estimate of relative risk.  However, results of another study 
showed that general cognitive functioning, processing speed, and delayed verbal memory 
had an estimated predictive accuracy of 79% (Fleisher et al., 2007).  None of 
hippocampal volume, ventricular volume, APOE4 genotype, and/or demographic 
variables improved the predictive accuracy of the model.  In contrast, more recent studies 
have noted a combination of imaging and neuropsychological variables as possessing the 
best predictive validity.  For example, Devanand and colleagues (2007) found that a 
combination of age, general cognitive functioning, delayed verbal memory, processing 
speed, hippocampal volume, and entorhinal cortex volume best predicted conversion 
from MCI to dementia.  Similar findings were also noted by Gomar and colleagues 
(2011).  In this study, only delayed verbal memory and temporal lobe cortical thickness 
remained significant at the multivariate level.  As can be seen, later models have included 
both cognitive and imaging variables to achieve the greatest level of predictive accuracy, 
commensurate to the findings of the current study.   
  Hypothesis #8: What diagnostic criteria can be used to construct an optimal 
screening model? 
For example, does a 1.0 or 1.5 SD cutoff using age- and education-adjusted scores on 
tests of neuropsychological functioning yield more acceptable inclusion rates in 
application of the screening model? Also, does using premorbid intelligence increase 
the psychometric properties of a screening model? Finally, does allowing for some 
minor difficulties with ADLs yield a more optimal screening model?  It is 
69 
 
hypothesized that using a 1.0 SD cutoff will be preferable to using a 1.5 SD cutoff, 
taking premorbid intelligence into account will increase the psychometric properties 
of the screening model, and allowing for some minor trouble with ADLs will further 
increase the psychometric properties of a screening model.     
 As can be seen in Table 12, the number of patients classified as normal were 
strikingly similar across diagnostic systems.   Relative consistency across diagnostic 
system was also observed for patients classified as AD.   The number of patients 
identified as MCI and converting to dementia (see Table 12), however, varied across 
diagnostic system because many patients were not able to be classified using proposed 
diagnostic criteria.  To retain a high level of consistency among diagnostic systems, 
attempts were made to use ADNI criteria whenever possible.  Consequently, the same 
cutoffs on the MMSE and CDR used for ADNI classification were used for the proposed 
diagnostic criteria as well.   However, the introduction of a measure of daily functioning 
and associated cutoff caused a considerable number of patients to be unclassifiable using 
proposed criteria.  As noted by Teng and colleagues (2010), a FAQ score >5 
demonstrates good utility for differentiating AD from MCI.  Thus, for proposed criteria, 
this cut-score was utilized as a diagnostic criterion.  However, a subsequent issue was 
encountered when applying the criteria that included daily functioning because its 
inclusion led to discrepancies among MMSE, CDR, Logical Memory – II, and FAQ 
scores.  For instance, using proposed criteria #1, a patient with an MMSE of 27, CDR of 
0.5, Logical Memory – II score falling more than 1.0 SD below the mean, and FAQ score 
of 6 would also be unclassifiable because the obtained FAQ score lies above the cutoff 
proposed by Teng and colleagues (2010) when all other scores lie within the MCI range 
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according to ADNI criteria.  It should be noted, however, when using only FAQ and 
Logical Memory – II scores as diagnostic criteria, almost all of the unclassified patients 
would have been classified as MCI, and the psychometric properties of the resulting 
models were very similar to those listed in Table 18.   
Neurocognitive Cutoff (i.e., 1.0 vs.  1.5 SD)  
 The percentages of patients who converted from MCI to dementia according to 
each diagnostic system are listed in Table 12.  However, because of the widely varying 
estimates of conversion found in the literature, these percentages are not useful when 
comparing the efficacy of the different screening models.    
 Although all subjects in the current study were part of the ADNI database, the 
application of different diagnostic criteria essentially divided this one sample into four 
samples: one sample using ADNI diagnostic criteria and three samples using proposed 
diagnostic criteria.  Thus, comparisons of performance measures (i.e., pseudo-R2 and 
AUC) can be made across samples/diagnostic systems (see Table 18).  When evaluating 
the different diagnostic systems and associated models in this way, one cardinal rule must 
be followed:  pseudo-R2 and AUC for a model should not be considered in relation to the 
sample from which they were derived.  When evaluating the models in this manner, the 
model derived using Proposed Criteria #1 (i.e., the model utilizing a 1.0 SD cutoff and 
allowing for scores ≤5 on the FAQ) appears to have a slight advantage to the model 
derived using Proposed Criteria #2 and a clear advantage to other models.  In fact, the 
model constructed using Proposed Criteria #1 was the best performing model whenever 
this general rule was followed.  Taken in combination with the observation that Proposed 
Criteria #1 and Proposed Criteria #2 had the best pseudo-R2 and AUC in relation to the 
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sample from which they were derived, it is clear that Proposed Criteria #1 yielded the 
best screening model.  Thus, it appears that a 1.0 SD cognitive cutoff is preferable to a 
1.5 SD cutoff.   
Daily Functioning    
 One method to evaluate the usefulness of the different diagnostic systems is to 
compare the number of predictors used in the final conversion model.  Across the five 
models, the number of included predictors ranged from 11 to 23.  Although still a large 
number of predictors, it would be easier to work with a model containing 11 predictors 
than it would be to work with a model containing 23 predictors.  However, ease only tells 
a small part of the story because performance of the model in predicting conversion is 
much more important.  Although these five models cannot be directly compared with 
statistical methods, statistics can be used for evaluative purposes.  For example, the 
psychometric properties of the models in relation to their specific diagnostic criteria can 
be compared (see Table 18).  When considering pseudo-R2 and AUC as performance 
measures, Model #1 and Model #2 have a clear advantage and are almost equal in utility.  
Interestingly, both of these models were derived from diagnostic systems that took into 
account scores from a measure of daily functioning (i.e., FAQ).  Thus, from this limited 
method of comparison, it appears that allowing for some decrements to daily functioning 
(i.e., allowing for scores ≤5 on the FAQ) improves the utility of a diagnostic 
classification system.     
Premorbid Intelligence 
  Contrary to a priori hypotheses, premorbid intelligence did not appear to increase 
the efficacy of a screening model in this cohort of people with MCI.  Evidence of this 
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conclusion comes from two sources.  First, Proposed Criteria #3 was the only set of 
diagnostic criteria that took estimates of premorbid intelligence into account.  However, 
the model constructed using Proposed Criteria #3 produced the poorest performance 
measures when considered in relation to the sample from which they were derived (see 
Table 18).  Moreover, the model constructed using Proposed Criteria #3 was arguably the 
worst performing model across the different samples.  Second, evidence for the lack of 
utility of premorbid intelligence can be found in the individual neuropsychological 
predictors that comprise the different models.  For each neuropsychological measure, 
three values were considered: raw score, normative-corrected z-score, and normative-
corrected z-score in relation to estimated premorbid IQ.  Interestingly, not even a single 
neuropsychological variable that took into account estimated premorbid IQ was retained 
in the neuropsychological model (Table 9) or any model derived utilizing ADNI and/or 
proposed diagnostic criteria (Tables 11 and 13-17).   
Follow-Up Analyses: Constructing the Most User-Friendly Equation for 
Neuropsychologists 
To a clinician, the model that would be the easiest to use would be the model with 
the most obtainable data.  For neuropsychologists, this model would be comprised of raw 
scores obtained from measures that can be administered during a brief 
neuropsychological evaluation.  Thus, an equation was constructed using only daily 
functioning and raw scores from core indices of neuropsychological measures 
administered as part of the ADNI study.  The resulting equation predicted conversion 
from MCI to AD with modest accuracy, and the optimal cut-score for this equation (-
3.32) was noted as obtaining sensitivity of 82% and specificity of 68% via ROC analysis.  
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To increase the facility of this model, an Excel spreadsheet has been provided that will 
calculate the predicted score for a patient.  Although an example, this spreadsheet 
demonstrates how prediction equations can be distributed for widespread clinical use.  
Directions for using the attached Excel spreadsheet are included in a separate document 
and are as follows:  
1. Enter FAQ Score into cell A2 (highlighted in green). 
2. Enter Logical Memory – II Total into cell B2 (highlighted in green). 
3. Enter Clock Drawing Total Score into cell C2 (highlighted in green). 
4. Enter AVLT Delayed Recall Total Score into cell D2 (highlighted in green). 
5. Enter the seconds needed to complete Trails A into cell E2 (highlighted in green). 
6. Enter ADAS-Cog Total Score into cell F2 (highlighted in green). 
7. Predicted Score for the patient will appear in cell G1 (highlighted in red).   
8. Compare the predicted score appearing in cell G1 to the cut-score of -3.32. 
9. Scores >-3.32 indicate an increased risk of conversion. 
10. Scores ≤-3.32 indicate a decreased risk of conversion.   
Limitations and Future Directions 
Despite the considerable findings presented in the current study, there are a 
number of limitations and future directions to be considered.  First, like most other 
multisite University-based studies, the current sample may not completely represent the 
population from which is was drawn.  Patients needed to agree to participate in several 
hours of testing, have an MMSE ≥24, and not have other central nervous system 
disorders.  This in all probability yields a select MCI group, and these results might not 
generalize to all patients with MCI.  Moreover, ADNI subjects represented a highly 
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educated, Caucasian cohort of older adults with MCI. Thus, the resulting models 
highlighted in this paper may not translate well to other races and groups with less 
education. Second, for people to be included in this study sample, a subjective memory 
complaint was required.  However, subjective memory complaints are a poor indicator of 
actual memory impairment (Reid & Maclullich, 2006) and may exclude some people 
with MCI.  Thus, future studies should not require a subjective memory complaint for 
inclusion.  Third, a score of ≥24 on the MMSE was required for study inclusion; 
however, the MMSE has a number of limitations that include age and education bias, 
limited focus on memory, and lack of an executive functioning component (Lorentz et al., 
2002; Kahokehr et al., 2004; Brodaty et al., 2006).  Fourth, as previously discussed, the 
assessment of functional decline in MCI is flawed.  Although a measure evaluating 
several aspects of higher-order functional skills was utilized in the current study, 
performance-based measures of daily functioning are superior and should be included in 
future studies.  Fifth, a large number of variables were considered when developing the 
models designed to predict conversion from MCI to dementia.  Because of the number of 
variables, multiple steps had to be conducted prior to developing a final model for each 
diagnostic system.  Future studies should limit the number of variables to ensure that the 
best predictors are included in conversion models.  For example, since a dearth of z-
scores were retained in final models, the number of neuropsychological variables can be 
reduced by only considering raw scores.  In relation to imaging, no PET variables were 
retained in a final model and a preponderance of retained imaging variables related to 
frontotemporal structures.  Thus, imaging variables can be significantly reduced by 
limiting consideration to MRI results of frontotemporal structures.  Sixth, although steps 
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were taken to cross validate the models outlined in the current study, cross validation 
with independent studies is clearly needed.  Moreover, clinical validation is necessary 
before conversion models can be used in clinical decision-making.  Seventh, the only 
type of MCI considered in the current study was aMCI.  However, other MCI types 
should be examined in future studies to investigate the utility of these findings in other 
MCI types as well as to develop models for MCI types other than aMCI.  Eighth, 
conversion was defined as progressing from MCI to dementia.  However, in the current 
study, dementia was defined according to diagnostic criteria for AD.  Future studies 
should evaluate conversion for other dementia types including both vascular dementia 
and frontotemporal dementia.  Also, pathological confirmation is needed to ensure that 
patients classified as converting from MCI to AD did not convert to a dementia type 
other than AD.  Finally, future studies should compare clinical judgment to the equations 
outlined in this study.    
 Implications 
 To date, although studies have been conducted that are useful to clinicians, no 
studies have provided clinicians working with people with MCI a viable tool to predict 
which patients will convert to dementia.  As a clinician, it is useful to know that a patient 
with MCI exhibited impairment on tests of episodic memory and that MRI results 
indicated mild diffuse cerebral atrophy because research has demonstrated that this 
patient has an increased risk for progressive decline.  However, albeit useful, this 
information leaves a clinician in a precarious position.  What should the patient and 
his/her family be told when questions about conversion occur? At present, the clinician 
can only answer these questions in vague terms. 
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However, in the current study, an equation was constructed that can be applied in 
clinical practice.  This model and associated cut-score offers neuropsychologists, as well 
as other health providers, an exciting opportunity.  With this equation, a 
neuropsychologist has the potential to answer questions about conversion with much 
more certainty.  Instead of giving vague answers, concrete probabilities based upon 
empirical research can be provided.  Moreover, regression based models and associated 
equations have the potential to enhance the referral base of neuropsychologists and 
expand their role on medical teams.  At present, typical referral questions for 
neuropsychologists working with older adults relate to diagnosis and differential 
diagnosis.  However, being able to give reliable and valid probabilities of conversion 
rates has the potential to allow neuropsychologists the opportunity to provide 
geriatricians, neurologists, and general practitioners a power tool when formulating 
medication and treatment regimens for older adults.  In regards to treatment, equations 
like the one presented in this paper can help identify people with MCI due to AD versus 
MCI due to a reversible condition.  Therefore, treatments can be better personalized 
based on the likelihood of a person’s developing dementia.   
Beyond simply enhancing the usefulness of a neuropsychologist, studies of this 
type have the potential to change the field of neuropsychology.  At present, the decision-
making process employed by neuropsychologists has several steps.  First, medical 
records are examined for the referral question and factors of interest.  Second, the patient 
and family are interviewed so a detailed medical and cognitive history can be obtained 
with emphasis given to the onset and progression of cognitive and movement related 
symptoms.  Third, a test battery of varying length is chosen and administered.  Fourth, 
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scores on the measures comprising the battery are calculated, and performance is 
considered in relation to demographically-matched peers.  Fifth, these results are 
considered in relation to findings garnered from the records’ review and interviews that 
the neuropsychologist deems important.  Seventh, the neuropsychologist conducts a 
sometimes lengthy and exhaustive literature review in an attempt to compare the patient’s 
profile in relation to empirical research.  Finally, a diagnostic impression is rendered.   
If this process appears inefficient and suboptimal, that is because it is.  Further, 
this process relies heavily on clinical judgment and places a clinician in the position to 
violate numerous decision-making contraindications (e.g., overreliance on salient data, 
human cognitive limitations, etc.).  However, with regression models, many steps in this 
process can be excluded, and the reliability and validity of diagnostic impressions 
standardized and greatly enhanced.  In addition, regression based models have the 
potential to show which measures add incremental validity.  Thus, test batteries can be 
streamlined and tailored for possible differential diagnoses that were hypothesized (e.g., 
AD versus frontotemporal dementia versus vascular dementia) based upon the referral 
question and records’ review.  This likely means that test batteries can be shortened, 
placing less stress and discomfort on the older adult patient and allowing the 
neuropsychologist to see more patients.  Finally, quantitative representations of brain 
imaging should be utilized in clinical practice.  At present, MRI results are interpreted 
based upon subjective visual impressions of MRI images usually by a radiologist or 
neurologist.  In contrast, this method of interpretation is not utilized in research setting.  
Instead, quantitative analyses of imaging results are conducted.  Moreover, computer 
programs that yield quantitative analyses of MRI data are not readily available outside of 
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research settings, and clinicians are not receiving training on how to operate such 
programs.  For MRI models to be used, quantitative MRI data will be needed.  This step 
in the diagnostic process is important because this study has shown that a combination of 
imaging and cognitive variables possess the greatest potential for increasing diagnostic 
accuracy as it relates to MCI and dementia.  Clearly, more widespread use of quantitative 
imaging data in clinical practice is needed.   
 Conclusion 
  At present, the diagnostic criteria for MCI are varied and able to be interpreted 
and implemented in different ways depending on the judgment of the clinician.  Because 
of this issue, a wide range of incidence, prevalence, and conversion rates are found in the 
research literature.  At its conceptual core, MCI is a term that was designed to describe 
people in the earliest stages of cognitive decline secondary to dementia.  Because of 
issues inherent in these criteria, people with a wide range of non-dementing illnesses are 
being diagnosed with a predementia syndrome.  Thus, many people diagnosed with MCI 
will have cognition and functional abilities that stay the same or even improve.  In the 
current study, it was proposed that the best way to improve MCI diagnostic criteria is to 
put more of an emphasis on conversion to dementia.  After all, if a person does not 
convert to dementia, a diagnosis of a predementia syndrome seems rather unnecessary.  
Moreover, by putting more of an emphasis on conversion when formulating diagnostic 
criteria, questions raised by the patient and his/her family that relate to conversion 
probabilities can be better answered.    
In the current study, a model was constructed using MRI and cognitive variables that 
was able to predict conversion from aMCI to AD with a high degree of accuracy (see 
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Table 11).  Using the equation derived from the model and its corresponding cut-score, a 
patient could be told with 66% accuracy that he/she would convert to dementia within the 
next year or with 99% accuracy that he/she would not convert to dementia within the next 
year.  The cut-score was selected to optimize sensitivity and identify a large majority of 
people who would convert.  However, different cutoffs could be selected for different 
purposes, thereby, increasing the accuracy of a positive test result.  Although equations 
like this have the potential to drastically improve the way clinicians diagnose dementing 
diseases, a number of issues concerning their application was illustrated in this paper 
(e.g., quantitative MRI data is not readily available).  Thus, a simple user-friendly model 
was constructed that utilizes only information that can be obtained during a brief 
evaluation (see Table 19).  The resulting model was used to predict conversion with 
modest accuracy.  In addition, this model was also used to demonstrate the ease of use of 
such an equation if an Excel spreadsheet and directions are included.  Finally, a number 
of other models were constructed to test the utility of different diagnostic systems.  As 
expected, the classification system with the best predictive validity utilized a cognitive 
cutoff of 1.0 SD on Logical Memory – II and allowed for some level of functional 
decline (i.e., scores ≤5 on the FAQ).  The equation derived from this model included 
variables representing functional ability, neurocognitive performance, and MRI 
volumetric measures.  In summary, these results clearly indicate that MCI diagnostic 




 Table 1.  MCI Diagnostic Criteria and Current Recommendations 
Petersen Criteria  
(Petersen et al., 1997) 
MCI-R Criteria  
(Winblad et al., 2004) 
1. Presence of a subjective 
memory complaint 
1. Presence of a cognitive complaint from 
either the patient and/or family member 
2. Preserved general intellectual 
functioning 
2. Absence of dementia 
3. Demonstration of a memory 
impairment by cognitive testing 
3. Change from normal functioning 
4. Intact ability to perform ADLs 4. Decline in any area of cognitive 
functioning 
5. Absence of dementia 5. Preserved overall general functioning 
but possibly with increasing difficulty in 
the performance of ADLs 
Note.  MCI-R=mild cognitive impairment-revised 










Table 2.  MCI-R Subtype and Etiology (Winblad et al., 2004.)   
MCI-R Subtype Etiology 
amnestic-MCI (aMCI) (single 
and multiple domains) 
degenerative, vascular, metabolic, traumatic, 
psychiatric, other 
multiple domains, slightly 
impaired-MCI (mdMCI) 




degenerative, vascular, metabolic, traumatic, 
psychiatric, other 
Note.  MCI =mild cognitive impairment, MCI-R=mild cognitive impairment-revised 
    
 














Table 3.  Recommendations from the Alzheimer’s Group (Albert et al., 2011) 
1. Cognitive concern reflecting a change in cognition reported by the patient 
or informant or clinician (i.e., historical or observed evidence of decline over 
time) 
2. Objective evidence of impairment in one or more cognitive domains, 
typically including memory (i.e., formal or bedside testing to establish level of 
cognitive function in multiple domains) 
3. Preservation of independence in functional abilities 
4. Intact ability to perform ADLs 
5. Not demented 
6. Provide evidence of longitudinal decline in cognition, when feasible 














Table 4.  Biomarkers Under Examination for AD (Albert et al., 2011) 
Biomarkers of Aβ deposition 
CSF Aβ42 
PET amyloid imaging 
Biomarkers of neuronal injury 
CSF tau/phosphorylated-tau 
Hippocampal volume or medial temporal atrophy by volumetric measures 
or visual rating 
Rate of brain atrophy 
FDG-PET imaging 
SPECT perfusion imaging 
Less well validated biomarkers: fMRI activation studies, resting BOLD 
functional connectivity, MRI perfusion, MR spectroscopy, diffusion 
tensor imaging, voxel-based and multivariate measures 
Associated biochemical change 
Inflammatory biomarkers (cytokines) 
Oxidative stress (isoprostanes) 
Other markers of synaptic damage and neurodegeneration such as cell death 
Note.  AD=Alzheimer’s disease, Aβ=beta-amyloid protein, CSF=cerebrospinal fluid, 
PET=positron emission tomography, FDG=fluorodeoxyglucose, SPECT=single photon 
emission tomography, MRI=magnetic resonance imaging, fMRI=functional magnetic 























Intermediate Positive, Untested Untested, Positive 




Highest Positive Positive 
MCI— 
unlikely  
due to AD 
Lowest Negative Negative 
Note.  AD=Alzheimer’s disease, Aβ=amyloid beta peptide, PET= positron emission  
tomography,  CSF=cerebrospinal fluid, FDG=fluorodeoxyglucose, sMRI=structural  





Table 6.  Current Recommendations for Standardization of MCI Diagnostic Criteria 
1. Intact general cognitive functioning as demonstrated by performance falling 
greater than 1.0 SD above the mean on a test of general cognitive functioning (e.g., 
DRS-2)    
2. Objective evidence of impairment in one or more cognitive domain as determined 
by performance falling at 1.0 SD or lower below the mean and/or estimates of pre-
morbid intelligence using age- and education-corrected scores on a 
neuropsychological battery (normative data corrected for race should be used 
whenever possible)  
3. Preserved overall general functioning but possibly with increasing difficulty in the 
performance of ADLs as determined by a measure of functional/ADL performance 
(i.e., >80% on the SE-ADL scale) 
4. Not demented 
Note.  MCI=mild cognitive impairment, SD=standard deviation, DRS=Dementia Rating  




















Table 7. Diagnostic Criteria for Classification Systems.  






Proposed Criteria #3 
CDR Normal 0 0 0 0 
MCI 0.5 0.5 0.5 0.5 
Mild AD 0.5 – 1.0 0.5 – 1.0 0.5 – 1.0 0.5 – 1.0 
LM II  Normal Above Cutoffs >-1.0 SD >-1.5 SD >-1.5 SD from VIQ 
MCI Below Cutoffs ≤-1.0 SD ≤-1.5 SD ≤-1.5 SD from VIQ 
Mild AD Below Cutoffs ≤-1.0 SD ≤-1.5 SD ≤-1.5 SD from VIQ 
MMSE Normal 24-30 24-30 24-30 24-30 
MCI 24-30 24-30 24-30 24-30 
Mild AD 20-26 20-26 20-26 20-26 
Memory  
Complaint 
Normal None None None None 
MCI Yes Yes Yes Yes 
Mild AD Yes Yes Yes Yes 
Daily  
Functioning 
Normal No changes ≤5 on FAQ ≤5 on FAQ ≤5 on FAQ 
MCI Essentially Normal ≤5 on FAQ ≤5 on FAQ ≤5 on FAQ 
Mild AD Decline ≥6 on FAQ ≥6 on FAQ ≥6 on FAQ 
Note. Differences between classification systems are highlighted. ADNI=Alzheimer’s 
disease Neuroimaging Initiative, CDR=Clinical Dementia Rating, LM=Logical Memory, 
MMSE= Mini-Mental Status Examination, MCI=mild cognitive impairment,  




























Table 8. Demographics for MCI Patients by Classification System. 




Criteria #1  
(n=191) 
Proposed  
Criteria #2  
(n=115) 
Proposed  
Criteria #3  
(n=255) 
Age 75 (54-89, 7.3) 73 (56-88, 7.3) 73.1 (66-86, 
7.5) 
74 (56-89, 7.5) 
Education 15.7 (4-20, 3.0) 14.6 (4-20, 3.3) 14.7 (4-20, 3.2) 15.5 (4-20, 3.1) 
Female 141 (35.5%) 79 (41.6%) 53 (46.5%) 101 (39.6%) 
Male 256 (64.5%) 111 (58.4%) 61 (53.5%) 154 (60.4%) 
Caucasian 371 (93.5%) 178 (93.7%) 106 (93.0%) 241 (94.5%) 








Note. For Age, Education, and MMSE, mean (range, standard deviation); for female, 
male, and Caucasian, number (percent). ADNI=Alzheimer’s disease Neuroimaging 











Table 9. Neurocognitive Model using ADNI Backward Elimination Method 
Variable Mean 
(Range) 
β p Example  
Patient  
Scores 
β X Example  
Patient Score 
Logical Memory  
– II   
4.95 (0-19) -.177 <.001 0 0 
Clock Score 4.20 (0-5) -.273 .021 4 -1.092 
AVLT Total 
Recall Trial 3 
6.34 (0-15) -.205 .012 5 -1.025 
AVLT Total  
Intrusion  
Trial 5 










2.08 (0-15) .112 .027 0 0 
Digit Span Z  
Score 
.41 (-2.67-2.67) .219 .080 .333 .073 
Animal Naming  
Total 
15.82 (2-60) -.064 .032 16 -1.024 




Trails A  43.93 (15-296) .014 .001 39 .546 
BNT Total  
Stimulus Cues 
2.65 (0-30) -.109 .003 4 -.436 
Constant  -.073   -.073 
Total     -2.078 
Note. Mean (Range)=mean and range. β X Example Patient Score refers to  multiplying 
unstandardized beta weight and patient score on associated variable. Total refers to sum 
of β X Actual Score. β=unstandardized beta weight, Actual Score=patient score on 
variable, ADNI=Alzheimer’s disease Neuroimaging Initiative, AVLT=Rey Auditory 















Table 10. Imaging Model using ADNI Backward Elimination Method 
Variable Mean (Range) β p Example  
Patient 
Score 









1799 (816-2805) -.002 .001 1959.830 -3.92 
Right  
Precentral Grey  
Matter 
.282 (.087-.488) 19.218 .003 .374 7.18 
Right Frontal  
Mid Orbital  
Grey Matter 
.432 (.061-.743) -19.653 .001 .528 -10.38 
Left Frontal 
Inferior Orbital  
Grey Matter 
.397 (.114-.577) 12.989 .058 .446 5.80 
Left Frontal  
Medial Orbital  
Grey Matter  
.45 (.13-.76) 11.335 .034 .527 6.0 





Right Amygdala  
Grey Matter 
.62 (.16-.86) -7.958 .024 .741 -5.90 
Left Superior  
Parietal Grey  
Matter 
.30 (.11-.55) -6.119 .103 .387 -2.37 
Left Superior  
Temporal Grey  
Matter 





.48 (.18-.71) 14.472 .001 .591 8.55 
Constant  68.101   68.101 
Total     -1.519 
Note. Mean (Range)=mean and range for MCI patients. β X Example Patient Score refers 
to multiplying unstandardized beta weight and patient score on associated variable, Total 
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed 
in mm3.β=unstandardized beta weight, Actual Score=patient score on variable, 





Table 11. Final Model using ADNI Criteria, Hand Selected Method 
Variable Mean (Range) β p Example  
Patient  
Score 
β X Example  
Patient Score 
AVLT Delayed  
Total 
2.67 (0-15) -.392 .109 2 -.784 
AVLT Total  
Intrusions  
Trial 2 
.46 (0-7) 1.006 .003 0 0 
Animal Naming  
Perseverations 
1.12 (0-13) .287 .022 1 .287 
BNT Total  
Semantic  
Cues 
2.65 (0-30) -.260 .006 5 -1.3 
ADAS-Cog Total  18.7 (0-30) .115 .030 24 2.76 
Logical Memory  
– II  
4.95 (0-19) -.052 .639 7 -.364 




983 (885-1036) -.079 .003 975.789 -77.087 
Right Precentral  
Grey Matter 
.282 (.087-.488) 32.456 .001 .342 11.1 
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Front Mid  
Orbital Right  
Grey Matter 
.432 (.061-.743) -26.645 .003 .467 -12.443 
Front Inferior 
Orbital Left  
Grey Matter 
.397 (.114-.577) 21.584 .064 .395 8.526 
Posterior Right  
Cingulum  
Grey Matter 
.333 (.120-.557) -13.578 .078 .376 -5.105 
Left Superior  
Temporal  
Grey Matter 
.423 (.151-.651) -13.125 .101 .427 -5.604 
Constant  76.564 .004  76.564 
Total Equation  
Score 
    -1.882 
Note. See Statistical Analyses section for description of Hand Selected Method. Mean 
(Range)=mean and range of MCI patients. β X Example Patient Score refers to 
multiplying unstandardized beta weight and patient score on associated variable, Total 
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed 
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable, 
ADNI=Alzheimer’s disease Neuroimaging Initiative, AVLT=Rey Auditory Verbal 
Learning Test, BNT=Boston Naming Test, ADAS-Cog=Alzheimer’s disease Assessment 
Scale-Cognition, CDR=Clinical Dementia Rating. 
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Table 12. Number and Percentage of Patients Identified as Normal, MCI, and Mild AD   
and  Converting from MCI to dementia.  






Normal 229 (27.9) 229 (27.9) 230 (28.0) 230 (28.0) 
MCI 397 (48.4) 191 (23.3) 115 (14.0) 255 (31.1) 
Mild AD 192 (23.4) 201 (24.5) 183 (22.3) 191 (23.3) 
Unclassified  0 197 (24.1) 290 (35.5) 142 (17.4) 
Conversions 164 (41.3) 47 (25.0) 42 (36.5) 61 (23.9) 
Note. For each cell, mean (%). Conversions=patients converting from MCI to dementia. 
Proposed Criteria #1 = ≤-1 SD on Logical Memory – II and <6 on the FAQ, Proposed 
Criteria #2 = ≤-1.5 SD on Logical Memory – II and <6 on the FAQ, Proposed Criteria #3 
= ≤-1.5 SD in relation to VIQ on Logical Memory – II and <6 on the FAQ (See Table 7 
for detailed description). ADNI=Alzheimer’s disease neuroimaging initiative, MCI=mild 
cognitive impairment, AD=Alzheimer’s disease, FAQ=Functional Activities 
















Table 13. Final Model using ADNI Criteria, Backward Elimination Method 
Variable Mean (Range) β p Example  
Patient  
Score 
β X Example  
Patient Score 
CDR Judgment .390 (0-2) 2.544 .019 .5 .05 
Logical Memory –II  4.95 (0-19) -.305 .003 0 0 
Digit Span z score .414 (-2.67-2.67) .344 .210 0 0 
Animal Naming  
Total Correct 
15.82 (2-60) -.066 .157 15 -.99 
Animal Naming  
Perseverations 
1.12 (0-13) .246 .034 2 .492 
BNT Stimulus Cues 2.65 (0-30) -.265 .002 7 -1.855 
Cumulative  
Temporal Lobe  
Atrophy 
983 (885-1036) -.085 .001 993.919 -84.48 
Middle Left 




-3.202 .020 2.253 -7.22 
Right Precentral  
Grey Matter 
.282 (.087-.488) 27.615 .001 .348 9.62 
Front Mid Orbital  
Right Grey Matter  
.432 (.061-.743) -18.282 .007 .590 -10.78 




Constant  80.697   80.697 
Total Equation 
Score 
    -4.946 
Note. Mean (Range)=mean and range of MCI patients. β X Example Patient Score refers 
to multiplying unstandardized beta weight and patient score on associated variable, Total 
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed 
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable, 
ADNI=Alzheimer’s disease Neuroimaging Initiative, BNT=Boston Naming Test, 

















Table 14. Final Model using Proposed Criteria #1(Model #1). 
Variable Mean (Range) β p Example  
Patient  
Score 
β X Example  
Patient Score 
CDR Judgment .366 (0-1) 5.063 .016 0 0 
FAQ 1.85 (0-5) 1.172 <.001 5 5.86 
Logical Memory I Total 5.91 (0-14) -1.748 <.001 8 -13.984 




6.465 .001 -1.0 -6.465 
Clock Score 4.15 (1-5) -.969 .033 2 -1.938 
Clock Copy Score 4.69 (2-5) 5.783 <.001 5 28.915 
AVLT Total Intrusion  
Trial 6 
1.11 (0-7) .810 .011 1 .810 
Digit Span Total 14.31 (5-24) 2.762 <.001 10 27.62 
Digit Span Forward  
Total 
8.19 (1-12) -3.773 .001 6 -22.638 
Digit Span Forward  
Length  
6.50 (3-8) 1.603 .067 5 8.015 
Digit Span Backward  
Length 
4.53 (2-7) -4.530 .001 4 -18.12 
Trails A  42.33 (17-150) .071 .028 42 2.928 




Trails A – B z score -.65 (-14.32- 
1.85) 
-1.756 .001 1.191 -2.091 
ADAS-Cog Total 20.29 (3.33- 
35.67) 
.619 .001 20 12.38 
Right Precental Grey 
Matter 
.25 (.09-.38) 121.155 <.001 .150 18.219 
Right Inferior Frontal  
Gyrus Grey Matter 
.31 (.11-.51) -43.195 .021 .222 -9.586 
Left Rolandic  
Operculum Grey  
Matter 
.35 (.15-.61) 83.692 <.001 .271 22.707 
Right Mid Cingulum  
Grey Matter 
.43 (.24-.62) -70.822 <.001 .355 -25.108 
Right Hippocampus 
Grey Matter 
.43 (.19-.72) -15.490 .017 .285 -4.421 
Right Pallidum Grey  
Matter 
.13 (.01-.60) 24.151 <.001 .428 10.342 
Right Mid Temporal  
Grey Matter 
.43 (.17-.67) -64.065 .006 .348 -22.314 
Left Mid Temporal  
Grey Matter 
.44 (.19-.65) 52.943 .008 .356 18.871 
Constant  -29.464   -29.464 
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Total Equation Score     -4.562 
Note. Mean (Range)=mean and range of MCI patients. β X Example Patient Score refers 
to multiplying unstandardized beta weight and patient score on associated variable, Total 
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed 
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable, 
CDR=Clinical Dementia Rating, AVLT=Auditory Verbal Learning Test, ADAS-



















Table 15. Final Model using Proposed Criteria #2 (Model #2). 
Variable Mean  
(Range) 
β p Example  
Patient  
Score 
β X Example  
Patient Score 
FAQ 2.18 (0-5) .873 .008 3 2.619 
Clock Copy Score 4.70 (3-5) 1.737 .130 5 8.585 
AVLT Initial Recall z score -.35 (-2.67- 
2.33) 
-2.015 .002 -1.667 3.358 
AVLT Total Errors Initial  
Recall 
.52 (0-5) 1.164 .021 1 1.164 
Animal Naming 
Perseverations 
1.39 (0-9) .577 .009 0 0 
Trails A score 42.92 (18- 
150) 
.054 .026 55 2.97 
Trails A – B z score -.85 (-12.44- 
1.8) 
.463 .135 -.277 -.128 
BNT Phonemic Cue  
Correct 
2.84 (0-14) -.412 .023 1 -.412 
Left Posterior Cingulum  
Grey Matter 
.34 (.14-.50) -50.114 .004 .304 -15.241 
Left Superior Occipital  
Grey Matter 
.28 (.10-.45) -47.125 .002 .282 -13.304 




Right Central  
Parahippocampal  
Gyrus 
.25 (.10-.46) 37.009 .004 .210 7.780 
Constant  -21.501   -21.501 
Total Equation Score     -7.096 
Note. Mean (Range)=mean and range for MCI patients. β X Example Patient Score refers 
to multiplying unstandardized beta weight and patient score on associated variable, Total 
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed 
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable, 
BNT=Boston Naming Test, FAQ=Functional Activities Questionnaire, AVLT=Auditory 














Table 16. Final Model using Proposed Criteria #3 (Model #3). 
Variable Mean (Range) β p Example  
Patient  
Score 
β X Example  
Patient Score 
FAQ 1.85 (0-5) .371 .002 3 1.113 




3311 (1649-4835) -.001 .003 2676 -2.676 
Right Mid  
Frontal Grey  
Matter 
.35 (.07-.61) -10.02 .007 .332 -3.329 
Left Heschl’s  
Gyrus Grey  
Matter 
.34 (.16-.56) 17.358 <.001 .282 4.898 
Right Inferior  
Parietal Grey  
Matter 
.36 (.15-.60) 8.235 .098 .317 2.614 
Constant  -8.562   -8.562 
Total Equation  
Score 
    -2.567 
Note. Mean (Range)=mean and range of MCI patients. β X Example Patient Score refers 
to multiplying unstandardized beta weight and patient score on associated variable, Total 
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refers to sum of β X Actual Score. Units of measurement for imaging variables are listed 
in mm3.  β=unstandardized beta weight, Actual Score=patient score on variable, 
FAQ=Functional Activities Questionnaire, ADAS-COG=Alzheimer’s disease 






















Table 17. Performance of Models across Classification System (β, p). 

















2.352, .393 -5.335, .316 2.380, .289 
Model #1 6.032,  
<.001 
3.199, <.001 9.190, .051 3.558, .002 
Model #2 3.026,  
.071 
-2.727, .417 7.862, <.001 .397, .851 
Model #3 .939, .590 5.426, .087 -7.532, .267 6.271, <.001 
Note. For each cell, unstandardized beta, p value. ADNI=Alzheimer’s disease 










Table 18. Performance of Models across Classification Systems (Pseudo R2, AUC). 
 ADNI Proposed  
criteria #1 
Proposed criteria  
#2 
Proposed criteria  
#3 
ADNI hand  
selected model 





.50, .91 .31, .82 .33, .81 .26, .76 
Model #1 .39, .88 .74, .97 .62, .94 .47, .89 
Model #2 .22, .81 .39, .87 .77, .97 .25, .80 
Model #3 .23, .82 .35, .86 .31, .83 .41, .88 
Note. For each cell, pseudo R2, AUC. Yellow highlighting indicates the pseudo-R2 and 
AUC of each model in relation to the Proposed Criteria from which they were derived. 
Blue highlighting indicates the best and red highlighting indicates the worst pseudo-R2 
and AUC of a model in relation to a validation sample/Proposed Criteria from which it 









Table 19. User-Friendly Model  
Variable Mean (Range) β p 
FAQ 4.29 (0-28) .083 <.001 
Logical Memory – II  4.95 (0-19) -.158 .002 
Clock Score 4.20 (0-5) -.176 .133 
AVLT Delay Total 2.67 (0-15) -.167 .035 
Trails A 43.93 (15-296) .010 .037 
ADAS-Cog Total 18.72 (0-67) .034 .129 
Constant  -3.456  
Note. Mean (Range)=mean and range of MCI patients. β=unstandardized beta weight, 
FAQ=Functional Activities Questionnaire, ADAS-Cog=Alzheimer’s disease Assessment 
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Appendix A: Model and Equation Derived from Neurocognitive Performances 
The resulting equation constructed from neurocognitive performance is as follows 
(see Table 9):                   (         [      ])  (               
      )  (                     )  (                     )  
(                              )  (                                 )  
(                              )  (                         )  
(                     )  (                                  )  
(                )  (                          )    
Examples may be useful for those not familiar with regression-based models (see 
Table 9). For this sample of people with MCI, the following means were observed: 4.45 
on Logical Memory II, 4.20 on Clock Drawing, 6.34 on AVLT Trial 3, 5.46 on AVLT 
Total Intrusions for Trial 5, -0.82 for AVLT Recognition z-score, 2.08 for AVLT 
Recognition Errors, 0.41 for Digit Span z-score, 15.82 on Animal Naming, 1.12 on 
Animal Naming Total Perseverations, 43.93 on Trails A, and 2.65 on BNT Stimulus 
Cues. Using average neurocognitive performances and the constant obtained for this 
model (-0.073), this sample of people with MCI would have an overall score of -2.08—
above the clinical cutoff of -2.32. This means the sample as a whole is demonstrating an 
increased risk of conversion.  
However, most applications of this model will likely occur at the individual level, 
and one such example can be found in Table 9. For this example (i.e., -0.073 – [0.177*0] 
– [0.273*4] – [0.205*5] + [0.203*0] + [0.339*1.333] + [0.112*0] + [0.219*0.333] – 
[0.064*16] + [0.176*3] + [0.014*39] – [0.109*4] = -2.078), the obtained score also lies 
above the clinical cutoff of -2.32, so conversion within a 2-year period is likely. For a 
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person who scored 8.0 on Logical Memory II, 5.0 on Clock Drawing, 7.0 on AVLT Trial 
3, 2.0 on AVLT Total Intrusions for Trial 5, 0.09 for AVLT Recognition z-score, 1.0 for 
AVLT Recognition Errors, 0.41 for Digit Span z-score, 17.0 on Animal Naming, 1.0 on 
Animal Naming Total Perseverations, 34.0 on Trails A, and 2.0 on BNT Stimulus Cues 
the equation based on neuropsychological performance would be as follows: -0.073 – 
[0.177*8] – [0.273*5] – [0.205*7] + [0.203*2] + [0.339*0.09] + [0.112*1] + 
[0.219*0.41] – [0.064*17] + [0.176*1] + [0.014*34] – [0.109*2] = -4.3047. This 
obtained scores lies well below the clinical cutoff of -2.32, so conversion over a one-year 
period is unlikely. For those interested, an Excel spreadsheet and instructions for use can 
















Appendix B: Model and Equation Derived from Neuroimaging Data 
 The resulting equation constructed from imaging variables is as follows (see 
Table 9): 
                 
(         [      ])  (                                         )  
(                               )  (                             
      )  (                                            )  
(                                         )  
(                                            )  
 (                                             )  
(                                  )  
(                                          )  
(                                           )  
(                                   )           
Examples of this regression-based model are provided in Table 10. For this sample of 
people with MCI the following means were observed: cumulative temporal lobe atrophy 
of 983 mm3, left hippocampus volume of 1799 mm3, right precentral grey matter of 0.282 
mm3, right frontal mid orbital grey matter of 0.432 mm3, left frontal inferior orbital grey 
matter of 0.397 mm3, left frontal medial orbital grey matter of 0.453 mm3, right posterior 
cingulum grey matter of 0.333 mm3, right amygdala grey matter of 0.62 mm3, left 
superior parietal grey matter of 0.30 mm3, left superior temporal grey matter of 0.432 
mm3, right cerebellum grey matter of 0.48 mm3. Using these averages and the constant 
obtained for this model (68.101), this sample of people with MCI would have an overall 
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score of -1.301—above the clinical cutoff of -2.04. This means the sample as a whole is 
demonstrating an increased risk of conversion. However, as with the neurocognitive 
model, most applications will likely occur at the individual level, and one such example 
can be found in Table 10. For this example (i.e., 68.101 – [0.063*991.279] – 
[0.002*1959.83] + [19.218*0.374] – [19.653*0.528] + [12.989*0.446] + [11.335*0.527] 
– [15.869*0.366] – [7.958*0.741] – [6.119*0.387] – [14.076*0.450] + [14.472*0.591] = 
-1.519), the obtained score also lies above the clinical cutoff, so conversion within a 2-
year period is likely. For those interested, an Excel spreadsheet and instructions for use 
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8/2009 – 7/2013  The Noble H. Kelley Psychological Services Center 
University of Louisville 
Provided peer-supervision to PhD level clinical psychology 
students in the areas of psychotherapy, assessment, and case 
management.   
 
8/2009 – 8/2011  University of Louisville’s Family and Geriatric Medicine 
Center 
Provided peer-supervision to PhD level clinical psychology 
students with older adult clients in the areas of psychotherapy, 
assessment, and case management.   
 
8/2009 – 8/2011 University of Louisville’s Geriatric Evaluation Team (GET) 
Provided peer-supervision to PhD level clinical psychology 
students in the areas of assessment, differential diagnoses, and 
providing consultation to an interdisciplinary team.  
 
1/2008 – 7/2009  NeuroRestorative: Brain Injury Recovery & Spinal Cord 
Rehabilitation  
Worked in a supervisory capacity as a full-time Behavior  
Specialist/Therapist at an inpatient, post-acute, residential facility 
for people with an acquired brain injury. Provided supervision to a 
wide range of professionals (i.e., occupational therapists, 
psychotherapists, nurses, speech language pathologists, and case 
workers) as well as direct care staff regarding the implementation 
of behavior support plans.   
 
1/2004 – 5/2007  Murray State University Psychological Center 
Provided peer-supervision to masters level clinical psychology 
students in the areas of psychotherapy, assessment, and case 






Guest lecturer. Presented neuropsychology module for students enrolled in an auditory  
science doctoral program (Fall 2013).   
 
Graduate Teaching Assistant (TA) for Psychology 201: Introduction to Psychology (Fall  
2012).  
 
Graduate Teaching Assistant (TA) for Psychology 582: Introduction to Clinical  
Psychology (Summer 2011).  
 
Guest lecturer. Presented neuropsychology module for students enrolled in an auditory  
science doctoral program (Fall 2011).   
 
Graduate Teaching Assistant (TA) for Psychology 582: Introduction to Clinical  




Invited peer reviewer for Psychiatry Research 
 
Invited peer reviewer for Neuropsychiatry 
 
Invited peer reviewer for BRAIN 
 
Louisville Chapter’s Multiple Sclerosis Family Weekend (November, 2011) 
Louisville Zoo – Louisville, KY 
Facilitated group discussion for people diagnosed with Multiple Sclerosis. 
 
West Louisville Health Fair (September, 2011)  
Westend Baptist Church – Louisville, KY 
Educated community members about services offered by the University of Louisville’s  
Psychological Services Center.   
 
National Memory Screening Day – Louisville, KY (November, 2010) 
University of Louisville 
Conducted dementia screenings and offered referral services.   
 
Sexual Assault Awareness Seminar – Murray, KY (April, 2007) 
Murray State University  
Provided crisis intervention and referrals for students following a seminar on sexual  
assault. 
 
Eating Disorder Awareness – Murray, KY (March, 2006)   
Body Fair, Murray State University  
Conducted eating disorder screenings and offered referral services.  
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